Duquesne University

Duquesne Scholarship Collection
Electronic Theses and Dissertations
Summer 8-8-2020

Isolation, Structure Elucidation, and Synthesis of Natural Products
from Marine Cyanobacteria
Keren Solomon

Follow this and additional works at: https://dsc.duq.edu/etd
Part of the Analytical Chemistry Commons, Marine Biology Commons, Medicinal Chemistry and
Pharmaceutics Commons, Medicinal-Pharmaceutical Chemistry Commons, Organic Chemistry
Commons, and the Pharmacology Commons

Recommended Citation
Solomon, K. (2020). Isolation, Structure Elucidation, and Synthesis of Natural Products from Marine
Cyanobacteria (Master's thesis, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1918

This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne
Scholarship Collection.

ISOLATION, STRUCTURE ELUCIDATION, AND SYNTHESIS OF NATURAL
PRODUCTS FROM MARINE CYANOBACTERIA

A Thesis
Submitted to the Graduate School of Pharmaceutical Sciences

Duquesne University

In partial fulfillment of the requirements for the degree of
Master of Science

By
Keren Solomon

August 2020

Copyright by
Keren Solomon

2020

ISOLATION, STRUCTURE ELUCIDATION, AND SYNTHESIS OF NATURAL
PRODUCTS FROM MARINE CYANOBACTERIA

By
Keren Solomon
Approved June 29, 2020
Kevin Tidgewell, Ph.D.

Aleem Gangjee, Ph.D.

Associate Professor of Medicinal Chemistry
Graduate School of Pharmaceutical Sciences
Duquesne University, Pittsburgh, PA
(Committee Chair)

Distinguished Professor of Medicinal Chemistry
Graduate School of Pharmaceutical Sciences
Duquesne University, Pittsburgh, PA
(Committee Member)

Marc Harrold, Ph.D.

Jelena M. Janjic, Ph.D.

Professor of Medicinal Chemistry
Graduate School of Pharmaceutical Sciences
Duquesne University, Pittsburgh, PA
(Committee Member)

Associate Professor of Pharmaceutics
Graduate School of Pharmaceutical Sciences
Duquesne University, Pittsburgh, PA

J. Douglas Bricker, Ph.D., Dean
School of Pharmacy and Graduate School of
Pharmaceutical Sciences
Duquesne University, Pittsburgh, PA

iii

ABSTRACT

ISOLATION, STRUCTURE ELUCIDATION, AND SYNTHESIS OF NATURAL
PRODUCTS FROM MARINE CYANOBACTERIA

By
Keren Solomon
August 2020

Thesis supervised by Dr. Kevin Tidgewell
This thesis describes the isolation, structure elucidation, and synthesis of natural products
from marine cyanobacteria. A crude extract from a cyanobacterium collected in Curacao showed
selective affinity for the dopamine D 5 receptor in a screen against a panel of CNS receptors. Due
to the high similarity of the D5 and D1 receptor, to date there are no known ligands that
differentiate them. Attempts to purify the compound responsible for this affinity led to the
isolation of the known compound caylobolide A. A second extract from a cyanobacterium
collected in Panama underwent bioassay-guided fractionation and yielded the novel compound
naranjamide, which showed activity against P. falciparum the protozoa responsible for malaria.
Syntheses of naranjamide and its nonmethylated analog were attempted in order to verify the
proposed structure and stereochemistry, as well as determine its mechanism of action.
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1. Natural Product Drug Discovery

“All that man needs for health and healing has been provided by God
in nature. The challenge of science is to find it.”
Paracelsus (1494-1541)

1

1.1. A Brief History of Natural Products
Since ancient times, civilizations have used plants and plant extracts for healing and
ameliorating diseases. Historical writings, such as Ebers Papyrus dating back to 1552 BC
of Ancient Egypt, and others dating as far back as 5000 BC Mesopotamia, described
using plants to determine pregnancy and to ease labor.1 Other important historical
marks include the discovery of the beneficial effects of cardiotonic digitalis extracts from
foxglove for treatment of heart disease symptoms, the use of willow and cinchona tree
bark for the treatment of fever, and the discovery of the effectiveness of poppy extracts
in the treatment of dysentery.2
In 1810, the term pharmacognosy was coined, describing the study of nature as a source
of drugs in a book titled Anglecta Pharmacognostica. Throughout the 19th century, with
improvements in technology, isolating and identifying the active compounds from their
natural producers became possible, and common. Morphine [figure 1A], responsible for
the analgesic and sedative effects of opium, was isolated from the seed capsules of the
poppy plant in 1804. Caffeine [figure 1A], a natural pesticide produced in plants, was
isolated in 1819 by Friedlieb Ferdinand Runge, and its structure determined in 1897 by
Hermann Emil Fischer. Runge also discovered quinine [figure 1A] from the bark of the
cinchona tree, still used today to treat malaria. By 1829, scientists discovered that salicin
[figure 1A] was responsible for the pain relief seen from ingesting willow bark extract,
and in 1838 salicylic acid [figure 1A] was isolated. However, salicylic acid was found to
be harsh on the stomach, and in the second half of the 19th century, acetylsalicylic acid
[figure 1A] was synthesized, providing a less irritating replacement for the original
molecule. Alexander Fleming discovered penicillin [figure 1A] in 1928, a natural

2

antibacterial compound produced by Penicillium chrysogenum growing on a petri dish
containing Staphylococci bacteria. The structure was confirmed by X-ray in 1945 by
Dorothy Crowfoot Hodgkin. The advances in analytical technology has allowed us to
understand the effects of traditional medicine, to isolate and replicate the active
ingredient, and to formulate and market it as modern medicine. Pharmacognosy is now
described by the American Society of Pharmacognosy as the study of natural product
molecules from sources of all biological kingdoms, most notably marine invertebrates,
plants, fungi, and bacteria, that are useful for their medicinal, ecological, gustatory, or
other functional properties.

morphine

caffeine

salicin

quinine

salicylic acid

penicillin V

acetylsalicylic acid

Figure 1A: Historical Natural Products
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1.2. Natural Products
Natural products are also known as secondary metabolites, compounds that are
naturally produced by biological organisms. Unlike primary metabolites, which are
indispensable and absolutely required for survival (i.e. carbohydrates, fats, proteins, and
nucleic acids), these natural products are not directly involved in the normal growth,
development, or reproduction of the organism. While an absence of them does not result
in immediate death, these secondary metabolites can affect the organism’s fitness by
playing a role in protection, competition, and inter- and intraspecies interactions.
Natural products have a broad range of functions. These functions include agents that
solubilize and transport nutrients, like siderophores which transport iron Fe +3 across
membranes in bacteria and fungi; pheromones that act as social signaling molecules
with other individuals of the same species, like queen mandibular pheromone secreted
by the queen bee to feed her attendants that gives the colony a sense of belonging;
communication molecules that attract and activate symbiotic organisms, like maltose
released from chlorella algae to its cnidarian host; 3 and chemical agents that are used
against competitors, prey, and predators, like the acacia trees which produce tannins in
their leaves when they’re preyed upon by giraffes. For many other compounds, the
ecological and/or biological function is still unknown.
Natural products are often structurally complex molecules that possess a well-defined
spatial orientation. These compounds have evolved to interact efficiently with their
biological targets, as their producers evolved alongside their target organisms. These
natural products have effect in human health as well; in fact, it was the identification of
cannabinoids in the 1960s that eventually led to the discovery and naming of the

4

cannabinoid receptors in the 1990s. 4 Research of these receptors and natural
cannabinoids led to the development of drugs for stimulation of appetite and
amelioration of nausea as well as symptomatic relief of cancer pain, 5 proving that these
natural products are a relevant starting point for drug development.

5

1.3. Marine Natural Products
With centuries of terrestrial pharmacognosy, scientists have more recently started
looking into the oceans and other aquatic environments as untapped sources of natural
products. The Ocean covers over 70% of the Earth’s surface and contains an estimated
95% of the Earth’s biosphere. According to fossil records, living organisms first
appeared in the sea more than 3.5 billion years ago. 6 Over time, they evolved many
different physical and chemical mechanisms to survive various environments, including
extreme temperature, salinity, pressure, oxygen levels, and sunlight, to overcome effects
of mutation, and to survive infection, fouling, and overgrowth of other organisms. For
immobile organisms, chemical adaptations would need to be extremely potent due to
the diluting effect of the ocean water.
The diverse chemical features and wide range of biological activities of marine natural
products have established them as a source of chemodiversity. 7-8 With recent advances
in technology, including SCUBA (self-contained underwater breathing apparatus) and
submersible ROVs (remotely operated vehicles), shallow water and deep sea organism
collections are now possible. Purified compounds from these collections are now able to
be detected in sub-milligram quantities with the help of modern analytical equipment.
Improvements in organic chemistry strategies enable practical syntheses of these
diverse natural products. These available technologies have made discovery, structure
elucidation, and synthesis of natural products from marine sources a more feasible and
attainable goal.
To date, more than 30,000 publications have been listed in the major database of
marine natural products, MarinLit, 9 indicating the enthusiasm of the scientific

6

community towards the discovery of new drug leads from marine habitats. According to
the latest review by Carroll, 10 1490 new compounds were isolated from marine
organisms in 2017, a number which has risen steadily from the beginning of the century
[figure 1B].

number of new compounds

1700
1500
1300
1100
900
700
500
2000

2005

2010

2015

2020

year
Figure 1B: Number of Marine Natural Products Discovered by Year10-25

1.3.1. Marine Natural Products: Biologically Active Compounds
Marine natural products display a superior chemical novelty when compared with
terrestrial natural products. Kong et al26 compared molecular scaffolds in the Dictionary
of Natural Products to those in the Dictionary of Marine Natural Products, and showed
that approximately 70% of molecular scaffolds in the Dictionary of Marine Natural
Products are exclusively utilized by marine organisms. Marine natural products usually
possess more long chains and large rings, especially 8- to 10-membered rings. Marine
natural products also have more nitrogen atoms and halogens, notably bromines, and

7

fewer oxygen atoms, suggesting that marine natural products may be synthesized by
more diverse biosynthetic pathways than terrestrial natural products. 27
This chemodiversity is reflected by varied biological activity, and has led to several
approved drugs from marine sources. 28-29 Cytarabine and vidarabine [figure 1C] were
the first FDA-approved marine-derived drugs, consisting of an arabinose sugar paired
with pyrimidine and purine nucleosides, respectively. They were developed from
naturally occurring nucleosides originally isolated from the Caribbean sponge Tethya
crypta, namely spongouridine and spongothymidine [figure 1C], consisting of thymineand uracil-arabinose, respectively. Both of the synthetic nucleosides can incorporate
into the DNA, however, the arabinose ring in the synthetic drugs prevents the DNA
strand from growing, therefore, killing the cell. The drugs are used for cancer therapy,
and vidarabine is also used in herpes virus infections. Trabectedin [figure 1C], a marine
alkaloid isolated from the tunicate Ecteinascidia turbinate, gained EU approval for the
treatment of soft tissue sarcoma. It acts by blocking DNA binding of the oncogenic
transcription factor FUS-CHOP. Eribulin mesylate [figure 1C], a structurally simplified
macrocyclic ketone analog of the potent cytotoxic compound halichondrin B first
isolated from the marine sponge Halichondria okadai in 1986, is FDA approved for
metastatic breast cancer. Eribulin acts by binding to and inhibiting microtubule
dynamics. Ziconotide [figure 1D], a synthetic equivalent of the naturally occurring ωconotoxin peptide isolated from cone snail (Conus magus) venom, was approved for
severe chronic pain management. It is an N-type voltage-gated calcium channel blocker,
inhibiting the release of pro-nociceptive neurochemicals in the brain and spinal cord,
resulting in pain relief 1000 times more efficacious than morphine. These are just some
examples of marine-derived compounds with significant biological activity.
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Cytarabine (1969)

Vidarabine (1976)

Trabectedin (2007)

spongouridine

spongothymidine

Eribulin Mesylate (2010)

halichondrin B
Figure 1C: Marine Natural Products and Approved Drugs
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Ziconotide (2004)
Figure 1D: Marine Natural Products and Approved Drugs
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1.4. Marine Cyanobacteria
“Water blooms” in freshwater lakes were reported in literature as early as the 1930s to
produce toxins that had negative effects on human and animal health, causing
“swimmers’ itch” to those who bathed, and illness and even death to animals who
ingested the water.30 It was this phenomenon that led Richard E. Moore to pioneer the
investigation of marine blooms of what was thought to be “blue-green algae”, leading to
the discovery of majusculamides A and B [figure 1E] from blooms of Lyngbya
majuscula Gomont, a marine cyanobacteria, in 1977.31

Figure 1E: Majusculamide A/B

Cyanobacteria are a phylum of prokaryotic bacteria with fossil records dating back to 3.5
billion years ago. They inhabit diverse environments, including fresh and saline waters,
terrestrial deserts and forests, and other extreme environments. Their name derives
from their color, which allows them to perform oxygenic plant-like photosynthesis, with
autotrophy as their dominant form of nutrition. Some cyanobacteria can grow in
anaerobic conditions, with sulfide as the electron donor for photosynthesis, while others
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have the ability to fix atmospheric nitrogen. These capabilities, along with their different
environmental surroundings, allow cyanobacteria to synthesize a vast collection of
varying organic compounds.
Another reason for their natural product diversity is their genome size. Unicellular
cyanobacteria of the chroococcales order have genome sizes of 1.7-4.0 Mbp, similar in
size to those of other bacteria. However, higher orders of cyanobacteria, including
filamentous orders oscillatoriales and nostocales, possess larger genomes of up to 6.0-10
Mbp,32 up to five times as large as other bacteria. Data suggests that genome evolution
and the relatively larger genome size in cyanobacteria occurred by a series of
duplications of a small ancestral genome, 33 whereas horizontal gene transfer has also
been thought to contribute to the size and variety of their genomes. 34 A larger genome
would allow to produce a wider range of enzymes, enabling cyanobacteria to synthesize
an assortment of organic compounds.
Cyanobacteria, with their diverse habitats and large genome, can produce a multitude of
natural products that contribute to their fitness. Being sessile organisms in the open
shallow waters, these natural products would need to be extremely potent to be effective
and beneficial. It is these reasons that scientists are investigating these organisms and
their chemical makeup, isolating interesting and complex secondary metabolites and
learning their biological activity, as leads for future drugs.
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1.4.1. Natural Products from Marine Cyanobacteria
Of the hundreds of compounds discovered from the ocean each year since 2011,
cyanobacterial natural products account for 2.3% of the total compounds discovered. In
2017, of the 1490 total compounds discovered from the ocean, 48 new compounds were
of cyanobacterial origin (3.2%).10
Cyanobacteria produce a wide variety of different metabolites. Molecular weight
distribution of known cyanobacterial compounds shows a bell-shaped curve, peaking
around the 400-500 kDa range [figure 1F], correlating to the range of drug-like
molecules, according to the Lipinski rules. 35 Structural classes from cyanobacteria
include saccharides and glycosides, terpenes, fatty acids, polyketides, non-ribosomal
peptides, and ribosome post-translationally modified peptides.

Number of Compounds

Molecular Weight Distribution of Cyanobacterial Natural Products
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70
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50
40
30
20
10
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Molecular Weight [Da]
Figure 1F: Molecular Weight Distribution of Cyanobacterial Natural Products
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1.4.1.1. Saccharides & Glycosides
Cyanobacteria have rarely been reported to produce exclusively sugar-based secondary
metabolites. However, this may be due to the extraction technique used by many natural
product chemists that study cyanobacterial metabolites, who do not focus on water soluble metabolites, as standard extraction and isolation procedures select against the
isolation of polar, sugar-based compounds.
An example of a sugar-based metabolite from cyanobacteria is cyclodextrin [figure
1G],36 isolated from a Hawaiian Tolypothrix byssoidea strain. This molecule, along with
a range of related metabolites produced, was found to have protective properties of
other toxic metabolites produced by this cyanobacterium.

1.4.1.2. Terpenes
Terpenes are a class of hydrocarbon compounds, constructed from isoprene units that
are combined to produce a variety of carbon-based skeletons, which can then be acted
upon by various enzymes to add functionality, such as cyclizations and oxidations.
Terpenes include the large structural groups of steroids and carotenoids, and have a
broad variety of functions, including incorporating into cellular wall structures.
An example of a cyanobacterial terpene is tolypodiol [figure 1G], 37 a meroditerpene
isolated from a cultured sample of Tolypothrix nodosa originally collected from a soil
sample from Nan Madol, Pohnpei. It was found to possess anti-inflammatory
properties.

14

1.4.1.3. Polyketides
Polyketides are a class of compounds created by polyketide synthases (PKS). The type I
PKS system found in cyanobacteria includes a series of catalytic domains linked together
that transfer and condense chains of acetate or propionate units, and then modify them
primarily via carbonyl reduction, dehydration into a cis-alkene, reduction into an
alkane, and finally cleavage of the chain to form the final compound. Additional
functionalizations like oxidations and cyclizations can occur as well.
Amantelide A [figure 1G] is an example of a cyanobacterial polyketide, which consists of
a 40-membered macrolactone ring, featuring a 1,3-diol and contiguous 1,5-diol units,
with a tert-butyl substituent. Amantalide A displayed potent cytotoxicity with
submicromolar IC50 against HT-29 colorectal adenocarcinoma and HeLa cervical
carcinoma cell lines, as well as antibacterial and antifungal activity. 38

1.4.1.4. Fatty Acid Derivatives
Fatty acids and fatty acid derivatives from cyanobacteria are created by the type II fatty
acid synthase (FAS), a series of enzymes that act similarly to those of the type I PKS, but
are separate catalytic units. The products synthesized are diverse in terms of size, degree
of saturation, patterns of unsaturation, alkylation, and hydroxylation. Often, fatty acids
are incorporated as sections within complex cyanobacterial natural products.
One of the more bioactive fatty acid derivatives from cyanobacteria is lyngbic acid
[figure 1H], which possesses low micromolar antifungal and cancer cell cytotoxic
properties. It is also a common component of other fatty acid derivatives, like the

15

malyngamides [figure 1H], some of which possess cancer cell cytotoxicity 39 and antiHIV properties40.

1.4.1.5. Peptides
Cyanobacteria produce a wide range of peptides and other amino acid-derived
metabolites. They range in size from conjugated amino acid pairs to polypeptides of over
1800 kDa. The majority of amino acids incorporated into cyanobacterial secondary
metabolites are nonpolar, with the second highest class being polar noncharged amino
acids, and most often in the L-form. Cyanobacteria can incorporate non-standard amino
acids, such as D-lysine, 3-amino-6-hydroxy-2-piperidone (Ahp), and homotyrosine
[figure 1H]. About half of the time, the amino acids are incorporated without
modifications; other times they include modifications like N- and O-methylation,
sulfation, halogenation, oxidation, cyclization, and polyketide extension. Common Ntermini include N,N-dimethylation, usually on valines. C-termini include a variety of
special caps, like dolaphenine as seen in naranjamide and barbamide, and a benzylmethoxypyrrolinone moiety, as seen in belamide A and caldoramide [figure 1H]. Both of
these specialized caps are composed of two condensed amino acids. These structural
features are typical of non-ribosomal peptides, which are synthesized by non-ribosomal
peptide synthetase (NRPS) domains.
Belamide A 41 [figure 1H] is a highly methylated peptide composed of five amino acids. It
was shown to disrupt the microtubule network in A-10 cells at 20 µM, and has an IC50 of
0.74 µM against HCT-116 colon cancer cells. Caldoramide42 [figure 1H] is another
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methylated peptide with the same C-terminal cap as seen in belamide A. It was found to
be active against HCT-116 colon cancer cells, with an IC50 of 3.9 µM.

1.4.1.6. Mixed Biosynthetic Molecules
Cyanobacteria are known for their ability to “mix & match” their syntheses.
Dolastatin 10 [figure 1I], probably the most famous of cyanobacterial natural products,
is composed mainly of peptides with added polyketide extension throughout the
molecule. It was isolated in 1993 and named after the sea hare Dolabella auricularia it
was initially extracted from. The peptide was present in very low yield, and ultimately, in
2001, it was discovered to be a product of the sea hare’s diet of marine cyanobacteria, in
particular the Symploca species.43 Dolastatin 10 has many closely related analogs, both
natural and synthetic. Dolastatin 10 and symplostatin 1 [figure 1I], differing only by
changing a valine to an isoleucine, are both potent microtubule inhibitors, thus
disturbing the normal cell division process. Dolastatin 10 reached a phase II clinical
trial, but was eventually unsuccessful due to its peripheral toxicity. It was ultimately
developed as an anti-body drug conjugate and was approved by the FDA in 2011 for
treatment of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
as brentuximab vedotin (Adcetrix ®) [figure 1I]. 7 Dolastatin 10 is composed of several
amino acids, including a terminal N,N-dimethyl valine, and an adjacent pair of ketideextended residues, isoleucine and proline. In both cases, these ketide-extended residues
are reduced in their β-ketone functionality to the alcohol, and then O-methylated. The
C-terminus is capped with dolaphenine.
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Largazole [figure 1I] is an example of a lipopeptide, composed of several unusual
structural elements, including two polyketide sections connected through a thioester, a
condensed cysteinyl-alanyl unit, which forms a thiazole ring, and a 4-methyl thiazoline
ring formed from a second cysteine residue. This was the first thioester linkage observed
in cyanobacterial natural products. 32 Largazole shows exceptional antiproliferative
activity with IC50 values to transformed cell lines in the low nanomolar range. Nontransformed cells were much less sensitive to the molecule, suggesting a drug target
unique to cancerous cells.

tolypodiol

cyclodextrin

amantelide A

Figure 1G: Natural Products from Cyanobacteria
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lyngbic acid

malyngamide S

malyngamide derivative

Ahp

homotyrosine

dolaphenine

benzyl-methoxypyrrolinone

naranjamide

barbamide

belamide A

caldoramide

Figure 1H: Natural Products from Cyanobacteria
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dolastatin 10

symplostatin 1

Brentuximab Vedotin (Adcetrix ®)

largazole
Figure 1I: Natural Products from Cyanobacteria
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2. Cyanobacterial Natural Products for Dopaminergic
Disorders

“This is the chemical formula for love:
C8H11NO2 + C10H12N2O + C43H66N12O12S2
Dopamine + Serotonin + Oxytocin
It can be easily manufactured in a lab, but overdosing on any of them
can cause schizophrenia, extreme paranoia, and insanity.”
Unknown
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2.1. Dopamine
Dopamine has an important role as a neurotransmitter by interacting with its receptors
in the CNS, which control a variety of functions, including learning, reward, motivation,
emotion, memory, cognition, feeding, sleep, and locomotion. Dysfunction in the
dopaminergic system is associated with several pathologies, including Parkinson’s
disease, schizophrenia, depression, and addiction. Peripherally, these receptors are also
involved in hormonal regulation, cardiovascular function, renal function, and olfaction,
among others.

2.1.1. Dopamine Receptors
There are five dopamine receptors that belong to the class A of rhodopsin-like GPCRs, 44
which are characterized by the presence of seven α-helical transmembrane domains.
These receptors have been classified into two families, the D 1-like and D2-like receptors,
depending on sequence homology, their association with G proteins, and their
pharmacology.45 D1-like receptors (D1 and D5) are almost exclusively localized postsynaptically on neurons, have a long C-terminal tail, do not contain introns, and have a
short third cytoplasmic loop, and are coupled to G-protein subunits Gαs and Gαolf, which
activate AC and lead to cAMP production and activation of PKA. The D 5 receptor is also
suggested to couple to Gαq. D 2-like receptors (D2, D3, and D4) are found both pre- and
post-synaptically, have a short C-terminal tail, contain up to six introns, and have a long
third cytoplasmic loop, and are coupled to Gα i/o/z, and inhibit AC, limiting cAMP
production and activity of PKA.46-49

22

Evolutionarily, the two dopamine classes originated independently, such that the ability
to bind dopamine was acquired twice during the evolution of biogenic amine receptors.
It is suggested that these amine receptors, including the dopamine receptors, likely
appeared before the cnidarian divergence, and that the D 1-like or D2-like divergence
from the ancestor took place before the separation of platyhelminthes, 50 or in other
words, before the divergence into symmetry, after the appearance of tissue
compartmentalization. These would also be the first phyla to gain motility, allowing
intentional hunting for prey. It appears that neither cnidaria nor platyhelminthes prey
on cyanobacteria, perhaps because of the natural products cyanobacteria produce that
could deter the organisms.

2.1.2. Dopamine D5 Receptors
In 1991, three genes closely related to the D 1 receptor were identified in the human
genome.51 One of the genes lacked introns and encoded a functional human dopamine
receptor, D5, whose deduced amino acid sequence is 49% identical to that of the human
D1 receptor. The D5 receptor displays a higher affinity and efficacy for dopamine
compared to the D1 receptor, and unlike the D 1 receptor, is constitutively active. 51 A
series of experiments showed that the C-terminus of the D5 receptor is responsible for
the constitutive activity of the receptor, which has only 30% sequence homology to the
D1 C-terminus.52 The transmembrane regions of the receptors, where ligands tend to
bind, however, share nearly 80% of their sequence, making selective ligands difficult to
find or design.
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Despite being transcribed by two distinct genes, little is known regarding the molecular
determinants that modulate the functional properties of these two receptors. This is in
large part due to the relatively low expression levels of D 5 receptors in neuronal
populations when compared to the widely distributed and more abundant D 1 receptor.
Another reason is the lack of available pharmacological tools and ligands that can
selectively differentiate these receptors. In fact, most studies have utilized knockout
models to determine the effect of the D 5 receptor. It is therefore important to find D 5selective molecules that will aid in studying the characteristics and functions of the D 5
receptor.

2.1.3. Dopamine D5 Receptor Functions
The D5 receptor was recently found to be expressed in human pituitary adenomas,
glioblastomas, colon cancer, and gastric cancer. Activation of the receptor with an
agonist in these cell lines suppressed their growth, inhibited MTOR activity, and
induced autophagy.53 The efficacy was correlated with levels of D 5 expression.
The D5 receptor is widely expressed in the cerebral cortex and hippocampus, regions
critically involved in spatial working memory function. Disruption of the dopamine D 5
receptor has been shown to impair spatial working memory and temporal order memory
function, all of which are higher order cognitive functions associated with the prefrontal
cortex. D5 knockout mice displayed impaired performance compared to their wildtype
littermates when a higher burden on working memory faculties was imposed. In
temporal order object recognition, mice that were heterozygous D5 (+/-) exhibited
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significant memory deficits, as did the complete knockout mice. Locomotion and
motivation did not appear to be D 5 dependent in this study.54
Dopaminergic neurons are known to play a critical role in pain modulation in several
areas of the CNS. D1-like receptors play an essential role in hyperalgesic priming, and
are likely stimulated by the dopaminergic projections from the hypothalamus. Genetic
ablation of the D5 receptors reduces acute pain responses and prevents hyperalgesic
priming in a sex-dependent manner, affecting male, but not female, mice. Male D 5
knockout mice displayed decreased basal heat sensitivity and decreased responsiveness
to irritant injection but had normal mechanical sensitivity. D 5 mRNA expression was
also higher in the spinal cord of male mice compared to females. Genetic ablation of the
D1 receptor showed the opposite sex-dependent effects, affecting only female mice. 55

2.1.4. Natural Products for Dopaminergic Disorders
There are several known plant natural products that are known to affect the
dopaminergic receptors. Antagonist levo-tetrahydropalmatine56 (L-THP) [figure 2A] is
found in both Corydalis genus and Stephania rotunda plants, and has been used in
traditional Asian medicine for its analgesic, sedative, and hypnotic properties. More
recently it has shown potential as an anti-craving agent.57 Mucuna pruriens is the bestknown natural source of levodopa (L-DOPA) [figure 2A], a dopamine agonist, the gold
standard for treatment of Parkinson’s disease caused by an underactive dopaminergic
system. These plants also produce 5-hydroxy tryptamine (serotonin) and psychedelic 5methoxy-N,N-dimethyl tryptamine.58 (-)-stepholidine59 (SPD) [figure 2A] from the
Chinese medicinal plant Stephania intermedia Lo has been in use for many years, and is
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described as a D 1 partial agonist and D2 antagonist. Its unique dual effects suggest that it
can restore the imbalance seen between D 1 and D2 receptors in schizophrenic
conditions, improving both the positive and negative symptoms of schizophrenia. It has
also been shown that SPD can relieve the motor symptoms of Parkinson’s disease when
administered with agonist L-DOPA.

L-THP

L-DOPA

(-)-SPD

Figure 2A: Dopaminergic Natural Products from Plants

2.1.5. Cyanobacterial Natural Products as Dopaminergic Ligands
At the time of writing this thesis, there are no known cyanobacterial compounds that
show effect on the dopamine receptors.
There has been little investigation of marine cyanobacterial natural products as ligands
for dopamine receptors; the majority of marine cyanobacterial extracts and compounds
discovered are primarily tested in cancer, antibiotic, and other toxicity-based assays for
activity. While cyanobacteria lack dopaminergic receptors, they do incorporate the
amino acid tyrosine, the precursor to dopamine, into their secondary metabolites;
dopamine receptors first appeared just a short time later on the evolutionary scale. It is
therefore possible that cyanobacteria have the potential to produce potent and selective
dopaminergic compounds.
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2.2. Cyanobacterial Natural Products as D 5 Receptor Ligands
Our lab tests all cyanobacterial extracts obtained against a wide panel of CNS receptors
at the PDSP. Several extracts have shown activity against one or more of the five
dopamine receptors. One of our extracts, with its nine fractions, showed consistent
activity at the dopamine D5 receptor, but not the D1 receptor, in seven of the eight
fractions sent for PDSP testing. These fractions piqued my interest, because at present,
there are no fully selective D5 ligands, because of its similarity to the D 1 receptor
previously mentioned. These fractions were therefore chosen to be purified in attempts
to isolate the compound(s) responsible for the D 5 activity.

2.2.1. Collection, Extraction, & Fractionation
A 150 mL sample of cyanobacterium was collected in June 2015 at a depth of 5-10 feet
off the coast of Cas Abao, Curacao, and given the collection code CUCA-060415-7. It was
described as a red filamentous mat in the sand. The cyanobacterial sample was put in a
mix of 1:1 sea water and ethanol immediately upon collection, and later stored in -20°C
upon return from Curacao to Pittsburgh.
In September 2016, the 150 mL sample of the cyanobacterium was extracted using
DCM:MeOH 2:1 for 30 minute soaks five times, and an additional soak was left
overnight at room temperature. The aqueous phase was separated from the organic
phase, which was dried and evaporated in vacuo to afford 662 mg of an oily crude
extract, given the internal code DUQ0024. The extract was then subjected to flash liquid
chromatography, using the gradient described in table 2A.
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DUQ

Mass [mg]

Hexanes

EtOAc

MeOH

0024A

<4

100

0024B

8

80

20

0024C

39.2

60

40

0024D

45.9

40

60

0024E

28.1

20

80

0024F

3.3

100

0024G

6.7

75

25

0024H

128.9

50

50

0024i

265.7

0

100

Table 2A: Fractionation Method of DUQ0024 and Masses Per Fraction

2.2.2. Psychoactive Drug Screening Program Assay
The initial fractions (0024B-i) were sent to PDSP for testing (0024A had less than 4 mg
of material and was not sent) on a variety of CNS receptors, including the five dopamine
receptors (D 1-5) and dopamine transporter (DAT). The extracts were first subjected to a
primary binding assay at a single concentration of 10 µg/mL to compete with the radiolabeled ligand [table 2B and 2C]. If the ligand is inhibited by 50% or more, the extract is
subjected to a secondary binding assay, where it is tested at 11 different concentrations
to determine the IC50 value, the value where the extract inhibits ligand binding at 50%
[table 2D and 2E]. [See section 2.4.5. for additional information on the PDSP assay.]
DUQ

D1

D2

D3

D4

D5

DAT

0024B

-6

-2

7

0

48

-55

0024C

-1

10

15

3

64

9

0024D

28

21

28

10

77

9

0024E

22

11

23

20

81

0

0024F

3

-6

16

8

76

4

0024G

3

-18

10

-1

70

-2

0024H

12

5

15

6

70

12

0024i

15

4

20

-3

50

-20

Table 2B: % Inhibition of Dopaminergic Receptors and Transporter
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DUQ

5HT2A

5HT3

M2

M3

M4

MOR

NET

SERT

σ1

σ2

0024B

-13

-13

18

-10

23

2

-9

-18

34

11

0024C

8

-2

-51

-24

-60

10

-10

-13

37

71

0024D

35

32

7

-7

35

61

-12

4

4

53

0024E

54

3

6

0

36

22

-5

17

44

48

0024F

67

-21

11

19

17

36

-39

8

61

55

0024G

38

-10

7

-2

17

35

-34

2

42

41

0024H

28

-28

-7

-9

10

27

-82

-13

28

42

0024i

17

-43

3

-2

45

2

-56

-54

39

32

Table 2C: % Inhibition of Other Receptors and Transporters

DUQ

D1

D2

D3

D4

D5

DAT

0024B

>10000

0024C

3465

0024D

2163

0024E

2121

0024F

1742

0024G

2740

0024H

2631

0024i

3029
Table 2D: IC50 [ng/mL] Against Dopaminergic Receptors and Transporter

DUQ

5HT2A

5HT3

M2

M3

M4

>10000

>10000

>10000

MOR

NET

SERT

σ1

σ2

0024B
0024C
0024D

3693
2503

0024E

5077

0024F

4015

5348

2605
3258

0024G

>10000

1289

2797

0024H

7781

0024i

8611
Table 2E:

4605
2054
IC50 [ng/mL]

>10000

Against Other Receptors and Transporters

Fractions 0024C-i showed activity of over 50% inhibition of the dopamine D 5 receptor,
without effect of the D1 receptor. This apparent selectivity of affinity for the D 5 receptor

29

is the reason that this extract was chosen to be further fractionated and explored for
pure compounds that would contain these properties and be responsible for this activity.

2.2.3. Isolation Procedure
Fractions 0024H and 0024i were chosen to be subjected to further purification for three
reasons: their larger size making isolation of enough material for structure elucidation
more likely, NMR data showing peaks in the aromatic region correlating to
dopaminergic ligands which require an aromatic moiety [figure 2B], and their mass
spectrometry with molecular weights in the 700-800 region which falls under the smallmolecule molecular weight of drugs [figure 2C].

Figure 2B: 1H-NMR of 0024 Fractions
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0024H
ESI+

0024i
ESI+

Figure 2C: MS of Fractions 0024H and 0024i

2.2.3.1. Fraction 0024H
Fraction 0024H, eluting with 50% MeOH in EtOAc, was subjected to normal phase
column chromatography, using a gradient of 0-100% MeOH in DCM and yielding seven
fractions (0024H1-7). Fraction 0024H6, with peaks in the aromatic region of the 1HNMR, was subjected to a reverse phase column, using a gradient of 30-100% MeOH in
H2O, yielding five fractions (0024H6A-E). Fraction 0024H6E, with the same peaks in
the aromatic region seen in 0024H6, was subjected to additional purification using
normal phase column chromatography, using a gradient of 0-100% MeOH in DCM.
Fraction 0024H6E4 [see figure 2D for fractionation details and figure 2E for 1H-NMR
spectra] yielded what seemed like a pure compound, and was subjected to detailed
analysis with a variety of NMR experiments. It was then concluded that the fraction was
not of a pure compound, and that the peaks in the aromatic region did not belong to the
main compound of the fraction.
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Figure 2D: Fractionation of 0024H6E4

Figure 2E: 1H-NMR of 0024H6E4 Fractionation
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2.2.3.2. Fraction 0024i
At the same time, fraction 0024i, eluting with 100% MeOH, was subjected to normal
phase column chromatography, using a gradient of 0-100% MeOH in DCM, yielding
seven fractions (0024i1-7). Fraction 0024i5, with the same peaks in the aromatic region
of the 1H-NMR as seen in 0024H6E4, was subjected to another normal phase column,
using a gradient of 0-100% MeOH in EtOAc, with a slower gradient between 20-60%
MeOH where 0024i5 eluted in the previous column, yielding seven fractions (0024i5AG). The 1H-NMR of fraction 0024i5F showed an 1H-NMR similar to that seen for
0024H6E4, without some of the minor peaks including those seen in the aromatic
region. Fraction 0024i5F was a known compound caylobolide A [see figure 2F for
fractionation details and figure 2G for 1H-NMR spectra]. [For more on caylobolide A,
see section 3.2.].

Figure 2F: Fractionation of 0024i5F
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Figure 2G: 1H-NMR of 0024i5F fractionation

Because caylobolide A was so dominant in the two initial fractions (0024H and 0024i)
as suggested by the 1H-NMRs [figure 2B] and MS [figure 2C], I combined the rest of
these fractions into 0024Hi in order to purify caylobolide A and to investigate the minor
compounds that gave the peaks in the aromatic region.
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2.2.3.3. Fraction 0024Hi
Fraction 0024Hi was subjected to normal phase column chromatography using a
gradient of 0-100% MeOH in EtOAc. The tubes were then combined based on MS to
give eight fractions (0024Hi1-8) [see figure 2H for 1H-NMR]. Fraction 0024Hi8 was
predominantly caylobolide A, with other minor compound(s), as is seen in the 1H-NMR.

Figure 2H: 1H-NMR of 0024Hi Fractions

2.2.3.4. Fraction 0024Hi7
Fraction 0024Hi7, with peaks in the aromatic region that were previously seen, was
then subjected to reverse phase column chromatography using 50-100% MeOH in H2O
and flushed with 0-100% EtOAc in MeOH. The tubes were combined based on mass
spectrometry spectra, yielding five fractions (0024Hi7A-E) [figure 2I]. 1H-NMR spectra
of fractions 0024Hi7B and 0024Hi7C [figure 2J] showed similar peaks in the aromatic
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region, the same peaks that were seen in 0024H6E4 and 0024i5F, and they were
combined. Mass spectrometry showed values of 743 and 765, along with a few other
peaks. This fraction (0024Hi7BC) was then sent to PDSP for testing for activity on the
dopamine D5 receptor, with promising results [tables 2F-2H]. The lower efficacy and
potency of this fraction compared to the original 0024H and 0024i fractions suggest
that this is an impure sample. Had it been pure, a higher efficacy (higher inhibition) and
higher potency (lower IC50) would have been seen compared to 0024H and 0024i. It is
also possible that the mass of the sample sent in for testing was inaccurate and was
smaller than the mass used to calculate the efficacy and potency, as the mass of the
sample sent is approximately the standard error of our scale (~3 mg). However,
additional peaks in the MS spectra add to the argument of an impure fraction.

DUQ

D1

D2

D3

D4

D5

DAT

0024H

12

5

15

6

70

12

0024i

15

4

20

-3

50

-20

51

-14

0024Hi7BC

Table 2F: % Inhibition of Dopaminergic Receptors and Transporter

DUQ

5HT2A

5HT3

M2

M3

M4

MOR

NET

SERT

σ1

σ2

0024H

28

-28

-7

-9
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27

-82

-13

28

42

0024i

17

-43

3

-2

45

2

-56

-54

39

32

0024Hi7BC

18

7

Table 2G: % Inhibition of Other Receptors and Transporters

DUQ

D1

D2

D3

D4

D5

0024H

2631

0024i

3029

0024Hi7BC

2998
Table 2H:

IC50 [ng/mL]

Against Dopaminergic Receptors and Transporter
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DAT

Figure 2I: Fractionation of 0024Hi7BC

Figure 2J: 1H-NMR of 0024Hi7BC Fractionation

Fraction 0024Hi7BC was then subjected to reverse phase HPLC using a gradient of 40100% MeOH in H2O, collecting by 254 nm wavelength, which corresponds to aromatic
or conjugated systems. One compound eluted at 254 nm, with an additional few peaks
showing at 210 nm. Since MeOH absorbs at 210 nm and skews the chromatogram, AcN
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can be used in its place and peaks can be collected based on 210 nm wavelength as well;
a future attempt to collect using the new method was halted due to global events.

2.2.3.5. Fraction 0024Hi2
Fraction 0024Hi2, with peaks in the aromatic region, was subjected to reverse phase
HPLC using a gradient of 50-100% MeOH in H 2O. Fractions were collected based on
254 nm wavelength, correlating to an aromatic or conjugated system in the molecule,
however, some of the peaks overlapped, resulting in four semi-purified fractions [figure
2K]. Fractions 9, 18, 29, and 33 were taken for MS and 1H-NMR [figure 2L]. Fraction
29, which overlaps with two other peaks, is thought to include barbamide or a similar
analog. The 1H-NMR [figure 2M] shows an aromatic region with a pattern
corresponding to a dolaphenine unit, with 1H d at 7.77 ppm, 1H d at 7.51 ppm, and 5H m
at 7.23 ppm, and MS [figure 2N] includes values of 461 and 483, corresponding to
barbamide’s mass of 460.

Figure 2K: HPLC Chromatogram of 0024Hi2 (blue: 210 nm, black: 254 nm)
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Figure 2L: HPLC Chromatogram of 0024Hi2 Collected Peaks (254 nm)

Figure 2M: 1H-NMR of 0024Hi H29

0024Hi2
H29
ESI+
Figure 2N: MS of 0024Hi2 H29
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The remainder of 0024Hi2 was subjected to reversed phase column chromatography,
using a stepwise gradient of 50-100% MeOH in H2O [figure 2O]. Due to lack of time and
global events, the project was halted at this point. Future steps for this project would
include isocratic HPLC purifications of fractions 0024Hi2C and 0024Hi2F to isolate the
compounds seen in peaks 19, 29, and 33.

Figure 2O: Fractionation of 0024Hi
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2.3. Conclusions
The dopaminergic system has been implicated in Parkinson’s disease, addiction
disorders, mood disorders, schizophrenia and more. Specifically, the D 1 and D5
receptors have been implicated in working memory functions and hyperalgesic priming,
and were shown to be expressed in different types of cancers. These studies were
completed using knockout models, as there are no known selective D 5 ligands to date,
hindering our understanding of the receptor in our brains and bodies.
While no dopaminergic compounds were found (yet) from this extract, our lab is
continuing our efforts to isolate cyanobacterial natural products that show effect on
dopaminergic receptors, specifically the D5 receptor. These natural products can then
serve as leads to develop agents that will aid in studying the receptor.

To date, there are no known cyanobacterial compounds that show effect on the
dopamine receptors. Our lab has shown that cyanobacteria, with their wonderful
library of natural products, can produce these elusive compounds, and much more.
This is a call for researchers in academia to continue to study marine cyanobacteria
and their natural products, to collaborate with labs of different fields, and to take
advantage of all the tools that we have within our reach, in order to see a fuller and
more complete picture of these natural products. The PDSP is a free tool, requires
minimal extract, and can give a bigger picture as to the abilities of the compounds that
these “water blooms” produce for us.
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2.4. Experimental Procedures
2.4.1. Biological Materials
The cyanobacteria sample was collected in Playa Cas Abao, Curacao [figure 2P] on June
4, 2015, and given the name CUCA-060415-7. Later, the collection CUSM-060515-3 was
added, based on the physical appearance of the sample. The sample was described as a
red filamentous mat in sand [figure 2P], at a depth of 5-10 feet. A small sample was kept
for microscopic imaging at the CARMABI station the same night [figure 2P]. The sample
was put into 1:1 sea water and ethanol, with a total volume of 150 mL. Once back in the
lab, it was kept in -20°C until extraction.

Playa Cas Abao © Google Maps

Playa Cas Abao © Google Maps

CUCA-060415-7 in the Ocean

CUCA-060415-7 Sample

CUCA-060415-7 zoom X7.5

Conrad Digital Scope CARMABI

Figure 2P: Cyanobacteria Collection in Curacao
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2.4.2. Extraction
Prior to extraction, a voucher specimen was taken and is kept in our lab with the ID
CUCA-060415-7 / DUQ0024.
The freshly thawed sample was extracted on September 6, 2016, using a mixture of 2:1
DCM:MeOH. It was soaked five times for 30 minutes each time (5 x 500mL), with a
sixth soak overnight. The combined extracts were concentrated in vacuo to give 660mg
of a dark green oil (sample was not fully dried and included sand), 0.56% of dry weight.
The dry weight of cyanobacteria sample was 118g.

2.4.3. Initial Chromatography
Extract DUQ0024 was subjected to forced-air column chromatography, using standard
grade silica gel from Sorbent Technologies (40-63 µM particle distribution, 60Å
porosity). The solvent system used is detailed in table 2A, each fraction was obtained
using 500 mL of solvent.

2.4.4. Psychoactive Drug Screening Program (PDSP) Assay
All of our extracts and initial fractions are sent to the National Institute of Mental
Health (NIMH) Psychoactive Drug Screening Program (PDSP) to be screened against a
set of CNS receptors. Compounds or extracts are first subjected to primary radioligand
binding assays at single concentrations of 10 µM or 10 mg/mL. Compounds that show a
minimum of 50% inhibition are then tagged for secondary radioligand binding assays to
determine the equilibrium binding affinity at the specific targets. In secondary binding
assays, the compounds or extracts are usually tested at 11 concentrations (0.1, 0.3, 1, 3,
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10, 30, 100, 300 nM or ng/mL, 1, 3, 10 µM or mg/mL). [See ref 60-61 for more
information.]
A 4 mg sample of each fraction (with the exception of 0024A) was sent to PDSP for a
complete CNS activity screen [see section 2.2.2. for results].

2.4.5. Chromatography
2.4.5.1. Fraction 0024H
Fraction 0024H was subjected to flash chromatography using a normal phase KP-Sil 10
g column with a gradient of 0-100% MeOH in DCM on a Biotage Isolera™ Prime. Tubes
were combined to yield seven fractions based on TLC and MS results.
Fraction 0024H6 was subjected to flash chromatography using a reverse phase SNAP
C18 12 g column with a gradient of 30-100% MeOH in H2O on a Biotage Isolera™
Prime. Tubes were combined to yield five fractions based on TLC and MS results.
Fraction 0024H6E was subjected to flash chromatography using a normal phase ZIP
Sphere 5 g column with a gradient of 0-100% MeOH in DCM on a Biotage Isolera™
Prime. Tubes were combined to yield five fractions based on TLC and MS results.

2.4.5.2. Fraction 0024i
Fraction 0024i was subjected to flash chromatography using a normal phase KP-Sil 10 g
column with a gradient of 0-100% MeOH in DCM on a Biotage Isolera™ Prime. Tubes
were combined to yield seven fractions based on TLC and MS results.
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Fraction 0024i5 was subjected to flash chromatography using a normal phase KP-Sil 10
g column with a gradient of 0-100% MeOH in EtOAc on a Biotage Isolera™ Prime. The
gradient slope was decreased from 20-60%. Tubes were combined to yield seven
fractions based on TLC and MS results.

2.4.5.3. Fraction 0024Hi
Fraction 0024Hi was subjected to flash chromatography using a normal phase KP-Sil 50
g column with a gradient of 0-100% MeOH in EtOAc on a Biotage Isolera™ Prime.
Tubes were combined to yield eight fractions based on TLC and MS results.
Fraction 0024Hi7 was subjected to flash chromatography using a reverse phase SNAP
C18 12 g column with a gradient of 50-100% MeOH in H2O and flushed with a gradient
of 0-100% EtOAc in MeOH on a Biotage Isolera™ Prime. Tubes were combined to yield
five fractions based on MS results.
Fraction 0024Hi7BC was subjected to high performance liquid chromatography (HPLC)
using a reverse phase Synergi-fusion 4µ, 150x10mm column from Phenomenex, with a
gradient of 50-100% MeOH in H2O on a Dionex UltiMate 3000.
Fraction 0024Hi2 was subjected to high performance liquid chromatography (HPLC)
using a reverse phase Synergi-fusion 4µ, 150x10 mm column from Phenomenex, with a
gradient of 50-100% MeOH in H2O on a Dionex UltaMate 3000. Four fractions were
collected based on peaks of 254 nm wavelength [figure 2L]. After several collections, the
remainder of the fraction was then subjected to flash chromatography using a reverse
phase SNAP C18 12 g column with a stepwise gradient of 50-100% MeOH in H2O and
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flushed with a gradient of 0-100% EtOAc in MeOH on a Biotage Isolera™ Prime. Tubes
were combined to yield six fractions [figure 2O].

2.4.6. Instruments
2.4.6.1. NMR Spectroscopy
NMR spectra were recorded on a Bruker 500 spectrometer at 499.60 MHz for 1H and
125.62 MHz for 13C.
Samples were dissolved in CD3OD (with the exception of 0024C-F, dissolved in CDCl3)
and tested in standard 5mm diameter NMR tube at room temperature. Chemical shifts
are reported in δ values, [ppm] units, relative to the standard TMS (δ=0), and coupling
constants reported in [Hz]. [See section 6.1. for more details.]

2.4.6.2. Mass Spectrometry
Mass spectra were recorded on an Advion Expression Benchtop Mass Spectrometer
using Electro Spray Ionization (ESI).

46

3. Cyanobacterial Natural Products as Antiproliferative
Agents: Caylobolide A

“Life will always find a way to continue. Always. Life will out.”
Amelia Shepperd, Grey’s Anatomy (2015)

“Life, uh, finds a way.”
Jeff Goldblum as Malcolm, Jurassic Park (1993)
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3.1. Natural Products with Antiproliferative Effects
Cyanobacteria produce many compounds with cytotoxic activity through a variety of
mechanisms of action. A possible explanation for this is that these compounds provide a
defense mechanism for the sessile cyanobacteria against mobile predators that may be
in their surroundings. Cyanobacteria may utilize these cytotoxic compounds by
excreting them to keep predators at bay, or by producing them only upon disturbance
leading to cessation of predation. There are a variety of mechanisms by which secondary
metabolites may act as antiproliferatives such as cell cycle arresters, caspase inhibitors,
mitochondrial membrane disruptors, lipid permeabilizers, and chemotaxic agents.
Cell cycle is a delicate mechanism that comprises cell growth and its division into two
daughter cells. Some substances are able to disturb the normal functioning of this
mechanism compromising cell viability, a consequence that can be directly related with
apoptosis. A common cellular damage induced by marine cyanobacteria compounds is
the disruption of microtubules and actin proteins, which are directly involved in mitosis.
The most frequent consequence is G2/M phase arrest,62 which is the mechanism of
action of the dolastatins, including dolastatin 10 [figure 3A].
Caspases are a family of cysteine aspartate proteases that act as the central executers of
apoptosis. Marine cyanobacteria produce several compounds that are capable of
inducing alterations on caspases as a pathway to induce cell death. Caspase-3 is the
most studied caspase concerning to apoptosis induced by natural products. 62 The
activity of caspase-3 protein is increased after exposure to symplostatin 1, dolastatin 10,
and curacin A63 [figure 3A].
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Mitochondria have essential functions in aerobic cells, and interferences in its normal
behavior are crucial to determine cell fate. Dysfunctions in mitochondria imbalances the
cell redox potential, inducing damages in cell components that can lead to apoptosis. 62
While no known cyanobacterial compounds have been studied in relation to the
mitochondria, aurilide [3B],64 a cyclodepsipeptide from the Dolabella auricularia sea
hare (the same sea hare thought to have produced dolastatin 10), is described to induce
dysfunction in mitochondria. HeLa cells treated with this compound exhibit
mitochondria fragmentation.
The broad spectrum of activities of polyols is thought to be due to their lipidpermeabilizing effects, due to their amphiphilic nature. The polyhydroxy moieties of
amphidinols have been shown to permeabilize phospholipid liposomes in the presence
of cholesterol within the layer.65 The lipid-permeabilizing effect was dependent on the
cholesterol content, suggesting the direct binding of these compounds to cholesterol,
leading to pore formation. SAR studies corroborated these results, with the polyene
region being critical to binding to the lipid bilayer, and the size of the pore being
dictated by the polyhydroxy region.38 An example of an amphidinol is amphidinol 6 66
[figure 3B], which was isolated from marine dinoflagellate, and was shown to have
sterol-dependent membrane permeability.
Cancer cell metastasis is enhanced by chemotaxis, the migration of a cell in response to
a chemical stimulus. Chemotaxis is observed in most organisms, including single-cell
and multi-cellular organisms. Single-cell organisms like bacteria will approach
nutritional chemicals but will flee from toxic ones, whereas multicellular organisms
utilize the phenomenon for single-cell functions, such as the movement of sperm toward
an egg, or of immune cells toward their targets. The process also enables some cancer
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cells to migrate from one location to another, triggering the development of cancers at
the new site. Because many cancers are not visible and do not present symptoms until
they grow sufficiently large, they may hide in other parts of the body for months or
years, despite the original cancer being eliminated. Therefore, the identification of a
chemical with the ability to block chemotaxis of cancer cells could provide an effective
strategy for cancer treatment as an anti-metastatic agent. Nuiapolide67 [figure 3B]
exhibits anti-chemotactic activity at concentrations as low as 1.3 µM against Jurkat cells,
cancerous T lymphocytes, and includes a G2-M phase cell cycle shift.

dolastatin 10

symplostatin 1

curacin A
Figure 3A: Cyanobacterial Natural Products with Antiproliferative Effects
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aurilide

amphidinol 6

nuiapolide
Figure 3B: Cyanobacterial Natural Products with Antiproliferative Effects

51

3.2. Cyanobacterial Macrolides as Leads for Antiproliferative
Agents: Caylobolide A
Caylobolide A [figure 3C] was isolated serendipitously while attempting to isolate
dopaminergic compounds in this extract [see section 2.2.3.2. for isolation details, figure
2F for procedure]. Caylobolide A was isolated as fraction 0024i5F; it was the major
compound in the extract, accounting for at least 40 mg of the 532 mg extracted, with
more left unpurified.

Figure 3C: Caylobolide A

3.2.1. Structure Elucidation
Fraction 0024i5F was subjected to MS analysis, showing m/z values of 785 and 797,
corresponding to M+23 and M+35, leading to a proposed molecular weight of 762 [figure
3D].
Initial 1H-NMR [figure 3E] suggested the compound could be a peptide, as multiple
peaks in the 3-4 ppm region and in the 1.5-2.5 ppm region correlate to α- and β-protons
of amino acids. However, after running additional NMR experiments [figures 3F-3J; see
section 6.2. for more information on NMR experiments], several conclusions were
made: (1) out of 42 carbons seen, there is only a single carbonyl carbon at 173.55, likely
an ester, (2) there are nine methines in the 3.5-4.0 ppm region, suggesting multiple
hydroxy moieties, (3) there are multiple methylenes with very similar values, and three
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methyl groups of which two are doublets and one is a triplet. All of this together
suggested a polyketide structure rather than a peptidic one.
Based on NMR and MS, we deduced the formula to be C 42O11H82; the general structure
of the molecule would be a hydroxylated lactone, with the carbonyl and ring system
accounting for the two degrees of unsaturation.

0024i5F
ESI+

0024i5F
ESI-

Figure 3D: MS of 0024i5F
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Figure 3E: 1H-NMR of 0024i5F
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Figure 3F: 13C-NMR of 0024i5F
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Figure 3G: HSQC of 0024i5F
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Figure 3H: 1H-1H COSY of 0024i5F
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Figure 3I: HMBC of 0024i5F
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Figure 3J: HSQC-TOCSY of 0024i5F (15-minute mixing time)

#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

δC
173.55
42.30
26.96
44.04
68.51

67.01

67.51
38.84
74.32
36.96

22.54
13.00
13.78
18.43

HSQC δH
--2.187, 2.397
2.246
1.306, 1.458
3.657

δC
C=O
13.00
CH2
13.78
CH
18.43
CH2
20.78
CH
20.87
CH2
21.41
CH2
21.51
CH2
21.51
CH
21.70
CH2
22.54
CH2
26.96
CH2
29.26
CH
32.15
CH2
36.38
CH2
36.56
CH2
36.59
CH
36.81
CH2
36.86
CH2
36.89
CH2
36.90
CH
36.94
CH2
36.96
CH2
36.96
CH2
37.05
CH
37.80
CH2
37.98
4.016
CH
m
38.84
CH2
42.30
CH
43.36
CH2
43.90
CH2
44.04
CH2
67.01
3.511
CH
67.51
1.524, 1.730
CH2
67.57
5.172
CH
68.51
1.687
CH
69.20
CH2
70.59
CH2
70.73
1.335
CH2
70.81
0.928
CH3
t
70.96
0.937
CH3
d
74.32
1.008
CH3
d
173.55
Table 3A: 0024i5F NMR Assignments [see figure 3K]*
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HSQC δH
0.928
0.937
1.008
1.500
1.509
1.416, 1.602
1.409
1.615
1.397, 1.610
1.335
2.246
1.355
1.128, 1.430
1.499
1.428
1.489
1.510
1.510
1.510
1.510
1.413
1.687
1.425
1.504
1.465
1.460
1.524, 1.730
2.187, 2.397
1.605
1.636
1.323, 1.485
4.016
3.511
3.853
3.657
3.775
3.589
3.579
3.570
3.557
5.172

CH3
CH3
CH3
CH2
CH2
CH2
CH2
CH2
CH2
CH2
CH
CH2
CH2
CH2
CH2
CH2
CH2
CH2
CH2
CH2
CH2
CH
CH2
CH2
CH2
CH2
CH2
CH2
CH2
CH2
CH2
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
C

3.2.2. Rediscovering Caylobolide A
While working on structure elucidation from NMR and MS data, an online search of the
molecular formula pointed towards the compound being caylobolide A, which was
described in the original paper 68 as a “unique polyketide lactone” isolated in 2002 from
a sample of Lyngbya majuscula collected in Cay Lobos, Bahamas in 1999. The
compound contains a 1,3,5-triol, as well as “an unprecedented repeating unit of a
contiguous pentad of 1,5-diols within the 36-membered macrocycle”, in agreement to
our structure elucidation efforts thus far.
A second set of NMR experiments was performed, this time in DMSO, in order to
compare our NMR data to that in the paper. The 1H-NMR spectrum [figure 3L, table 3B]
clearly showed the identity of our molecule was caylobolide A.

Figure 3K: Caylobolide A
Color-coded NMR assignment: Because caylobolide A has repeating units, NMR assignments were very
difficult. For this reason, I have assigned each type of carbon/proton a color, corresponding to possible
options of chemical shifts.
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Figure 3L: 1H-NMR of 0024i5F in DMSO to compare with Caylobolide A68

δH
0024i5F

#H

Mult

J [Hz]

5.02
4.51
4.39
4.29
4.21
3.79
3.62
3.55
3.45
2.28
2.08
2.08
1.60
1.16-1.57

1
1
1
3
4
1
1
1
1
1
1
1
1
53

dt
d
d
m
m
m
m
m
m
m
m
m
m
m

9.9, 2.9
4.5
4.6

1.13
1.03
0.85
0.85
0.85
3.34
2.51

δH
Cay 2002
5.02
*
*
*
*
3.85
3.63
3.55
3.45
2.28
2.08
2.05
1.60
1.58
1.56
1.55
1.54
1.51
1.50
1.45
1.36
1.35
1.32
1.26
1.23
1.16

#H

Mult

J [Hz]

1

ddd

9.5, 6.0, 3.0

1
1
1
1
1
1
1
1
1
1
1
1
1
1
7
1
1
1
6
3
1

dq
dq
dq

12.4, 6.0, 5.0
11.6, 4.5
11.6, 5.0

dd
m
dd
m

13.0, 8.5
8.5, 4.5
13.0, 4.5

1
m
1
m
3
m
0.88
3
t
3
m
0.85
3
t
3
m
0.83
3
t
H2O
DMSO
Table 3B: 1H-NMR Comparison of 0024i5F and Caylobolide A in DMSO

6.7
6.0
7.0

*The original paper had an error in the table and did not show values of the 4.0-5.0 ppm
range. However, the 1H-NMR spectra in the original paper’s supplemental information
was nearly identical to our 1H-NMR spectra and did show the peaks in the 4.0-5.0 ppm
range.
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3.2.3. Micro Electron Diffraction
As the original paper did not resolve the complete stereochemistry of the molecule, we
sought to do so via micro electron diffraction. Using the newly developed micro electron
diffraction (MED) technique utilizing cryo-electron microscopy (CEM), we attempted to
determine the absolute configuration of caylobolide A.
CEM is a relatively new method that utilizes the transmission electron microscope for
chemical structure elucidation, allowing structure determination of large and/or
dynamic macromolecular assemblies in solution without the need to crystallize the
molecule. Instead, it uses cryogenics, freezing the molecules in solution, thus also
protecting them from the electron beams.
MED is a technique similar to X-ray diffraction (XRD) which uses CEM to determine
molecular structures of small molecules in atomic resolutions from nanocrystals only a
few molecule layers thick. Because it makes use of electron beams, which are less
damaging than X-rays, high-quality diffraction data is producible from crystals one
billion times smaller than what is necessary for XRD. The best resolution to date is
~1Å. 69 This method would allow us to determine the relative stereochemistry of
caylobolide A. The relative stereochemistry from CEM could then be combined with the
data of the four stereocenters already determined to obtain the absolute stereochemistry
of all stereocenters in the molecule.
In order to obtain the best diffraction data, the product needed to be crystallized. In the
first crystallization attempt, the product was simply dissolved in DCM and allowed to
dry in the refrigerator. A second attempt was made using heated water. In both cases,
small crystals were formed on the sides of the vial.
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When sent for testing, both samples had formed crystals that were too small to obtain
sufficient data. We hypothesized that the molecule is likely too flexible to orient itself in
a single direction to form large enough crystals for successful diffraction patterns [see
figure 3M for images taken]. Also, throughout the project, the lab had been having
technical difficulties with the instrument, and after these two attempts, the project came
to an end.

Caylobolide A crystal X19000

Single diffraction pattern 0° tilt

All spots -30° to 30° projected

Figure 3M: Micro Electron Diffraction of 0024i5F
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3.2.4. Activity of Caylobolide A
Caylobolide A has been reported to exhibit cytotoxicity toward the human colon tumor
cell line HCT-116 with an IC50 of 9.9 µM, and did not show anti-fungal activity against
two strands of Candida.68 After being isolated in our lab, it was sent to the PDSP for
screening against the full panel of receptors, with no significant activity detected [tables
3C and 3D].

DUQ

D1

D2

D3

D4

D5

DAT

0024H

12

5

15

6

70

12

0024i

15

4

20

-3

50

-20

0024i5F

9

-5

-9

-14

20

-14

Table 3C: % Inhibition of Dopaminergic Receptors and Transporter

DUQ

5HT2A

5HT3

M2

M3

M4

MOR

NET

SERT

σ1

σ2

0024H

28

-28

-7

-9

10

27

0024i

17

-43

3

-2

45

2

-82

-13

28

42

-56

-54

39

32

0024i5F

31

-24

8

1

9

-5

-6

-16

40

47

Table 3D: % Inhibition of Other Receptors and Transporters
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3.3. Experimental Procedures

3.3.1. Biological Materials: See section 2.4.1.

3.3.2. Extraction: See section 2.4.2.

3.3.3. Initial Chromatography: See section 2.4.3.

3.3.4. Psychoactive Drug Screening Program Assay: See section 2.4.4.

3.3.5. Chromatography
Fraction 0024i was subjected to flash chromatography using a normal phase KP-Sil 10 g
column with a gradient of 0-100% MeOH in DCM on a Biotage Isolera™ Prime. Tubes
were combined to yield seven fractions based on TLC and MS results.
Fraction 0024i5 was subjected to flash chromatography using a normal phase KP-Sil 10
g column with a gradient of 0-100% MeOH in EtOAc on a Biotage Isolera™ Prime. The
gradient slope was decreased from 20-60%. Tubes were combined to yield seven
fractions based on TLC and MS results.
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3.3.6. Instruments
3.3.6.1. NMR Spectroscopy
NMR spectra were recorded on a Bruker 500 spectrometer at 499.60 MHz for 1H and
125.62 MHz for 13C.
Experiments for caylobolide A (1H, 13C, 1H-COSY, HSQC, HMBC, HSQC-TOCSY,
NOESY, CLIP-HSQC, DOSY) were recorded on a Bruker 500 spectrometer at 500 MHz
for 1H and 125.73 MHz for 13C at Carnegie Melon University.
Samples were dissolved in CD3OD or DMSO-d6 and tested in standard 5mm diameter
NMR tube at room temperature. Chemical shifts are reported in δ values, [ppm] units,
relative to the standard TMS (δ=0), and coupling constants reported in [Hz]. [See
section 6.1. for more details.]

3.3.6.2. Mass Spectrometry
Mass spectra were recorded on an Advion Expression Benchtop Mass Spectrometer
using Electro Spray Ionization (ESI).

3.3.6.3. Micro Electron Diffraction
The microscope is a ThermoFisher Tecnai TF20 equipped with a field emission gun and
a TVIPS XF416 camera, with a grid in a Gatan 626 cryo-holder. Data collection was
attempted using both room temperature and cryo-temperatures via cooling the holder
with liquid nitrogen after putting the grid in it. The software controlling the diffraction
data collection is TVIPS EM-Conos.
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4. Cyanobacterial Natural Products for Neglected
Tropical Diseases: Naranjamide

“If you think you are too small to make a difference, try spending the
night with a mosquito.”
African Proverb
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4.1. Neglected Tropical Diseases
Neglected tropical diseases (NTDs) are a diverse group of communicable diseases that
prevail in tropical and subtropical conditions in 149 countries, affecting more than one
billion people, and costing developing economies billions of dollars every year.
Populations living in poverty, without adequate sanitation, and in close contact with
infectious vectors and domestic animals and livestock are those worst affected. 70
Effectiveness of available medication is diminished by the emergence of resistant
pathogens and severe side effects associated with therapy. Because these diseases do not
pose a significant threat to the population of developed countries and the financial
return is minimal, the pharmaceutical industry is less focused on developing new agents
for these diseases. Instead, non-governmental organizations and academic research labs
are motivated to investigate and contribute lead molecules for treatments of these
diseases. Our lab is among the handful of academic research labs that explores natural
products of plant, fungal, and marine cyanobacteria origin in the search for new drug
leads using assays against various NTDs, including malaria, leishmaniasis, and Chagas
disease.

4.1.1. Neglected Tropical Diseases: Malaria, Leishmaniasis, and Chagas
Malaria is caused by Plasmodium parasites and spread by female Anopheles mosquito
bites. Plasmodium falciparum is the deadliest of the five species of the malaria parasite
that can infect humans. Vaccines are available, but treatment for infection is more
difficult than prevention. The current recommended first-line treatment by the WHO is
artemisinin-based combination therapy (ACT). Chagas disease, also known as American
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trypanosomiasis, is caused by the Trypanosoma cruzi parasite. It is spread by
Triatominae insects, also known as kissing bugs. The disease is curable if treated
immediately after infection; benznidazole and nifurtimox are both effective if started
immediately, but their effectiveness drops to less than 60% for those in the chronic
phase of the disease, about 1-2 months after initial infection. Leishmaniasis is caused by
Leishmania parasites and is spread by female phlebotomine sandflies. For some species
of Leishmania, a single dose of amphotericin B can cure up to 95% of infections. For
other species, such as L. donovani, the most severe visceral form of Leishmaniasis, an
effective drug has yet to be discovered. Currently, strategies to prevent transmission of
these infections via the insect vector include insecticide spraying and long-lasting
insecticide-treated bed nets. However, these are not 100% effective.

4.1.2. Natural Products for Treatment of Neglected Tropical Diseases
There are several approved antiprotozoal drugs of natural origin, including quinine,
artemisinin, amphotericin B, and paromomycin [figure 4A]. The Quechua of Peru,
Bolivia, and Ecuador were the first to discover the benefits of the cinchona tree to halt
shivering due to low temperatures. In the 17 th century it was used to treat the shivers
brought on by the febrile phase of malaria, and it was found to cure the disease. It was
only in 1820 that quinine was discovered as the active compound in the tree bark, which
is still used today to treat malaria. Artemisinin, 71 a sesquiterpene used to treat malaria,
was isolated in 1972 from the plant Artemisia annua, an herb traditionally used in
Chinese medicine. Amphotericin B,72 a polyketide used to treat leishmaniasis since
1958, was isolated in 1955 from Streptomyces nodosus, a filamentous bacterium
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collected from the soil around the Orinoco River in Venezuela. Its complete stereo
structure was determined in 1970 by X-ray crystallography of the N-iodoacetyl
derivative, and its first synthesis achieved in 1987. 73 Paromomycin, isolated in the 1950s
from Streptomyces rimosus, has been used since the 1960s to treat leishmaniasis.

quinine

artemisinin
paromomycin

amphotericin B
Figure 4A: Natural Product as Antiprotozoal Drugs
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4.1.3. Marine Cyanobacterial Natural Products as Leads for Antiprotozoal
Agents
While these frontline antiprotozoal drugs are of terrestrial origin, marine natural
products can also provide an important source of effective lead compounds. Protozoa
are single-celled eukaryotic organisms that evolved about 1.5 billion years ago and
require an aquatic habitat to thrive. 74 Cyanobacteria have evolved alongside these
organisms, and in some cases have even developed a mutual symbiosis; the amoeba
Paulinella chromatophora appears to have acquired autotrophy via relatively recent
endosymbiosis of a cyanobacterium.75 With their ability to chemically and
biosynthetically produce a plethora of different structural classes of compounds, and
their evolution alongside protozoal organisms, cyanobacteria likely have the potential to
produce potent and selective lead compounds with antiprotozoal activity.
In recent years, a growing number of studies have tested cyanobacterial extracts against
a panel of tropical parasites, including those responsible for malaria, leishmaniasis, and
Chagas disease, with encouraging results. Several marine cyanobacterial natural
products with antiprotozoal activity have been reported, including [figure 4B]
gallinamide A, carmabin A, dolastatin 10, dolastatin 15, dragonamide A, calothrixin A,
and herbamide B, with IC50 values between 100 pM to 7.7 µM against P. falciparum and
L. donovani [table 4A].76-81 Unfortunately, most of the compounds mentioned also
showed general cytotoxicity and were not subjected to further testing. Gallinamide A,
also known as symplostatin 4, showed no detectable toxicity to cancer cell lines,
including NCI-H460 human lung tumor cells and Neuro-2a mouse neuroblastoma
cells,76 and is suggested to have a different, more selective mechanism of action against
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P. falciparum. Treatment of P. falciparum-infected red blood cells with gallinamide A
resulted in the generation of a swollen food vacuole phenotype of the parasite. The
mechanism of action was suggested to be inhibition of falcipains, cysteine proteases that
are involved in hemoglobin hydrolysis of the host in the parasites’ food vacuole. Overall,
gallinamide A led to a significant reduction of parasites at nanomolar concentrations. It
is suggested through analog design that the methoxypyrrolinone unit is necessary and
responsible for this anti-malarial activity.77, 79, 82

IC50 [µM]

P. falciparum

L. donovani

T. cruzi

Vero Cells

HeLa

HT-29

gallinamide A77-79

0.05a, 8.4b

9.3

inactive

10.4

12

53

carmabin A80

1.4b

dolastatin 1080

100 pMa

dolastatin 1580

0.20a

calothrixin A80

0.058b

dragonamide A80

7.7b

herbamide B81
a
b

9.8

6.5

67.8

5.9

P. falciparum 3D7
P. falciparum W2

HeLa Cervical Carcinoma
HT-29 Colon Adenocarcinoma

Table 4A: Activities of Antiprotozoal Cyanobacterial Natural Products
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carmabin A

dolastatin 10

dolastatin 15

gallinamide A

herbamide B

dragonamide A

calothrixin A

Figure 4B: Antiprotozoal Natural Products from Cyanobacteria
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4.2. Naranjamide
In our efforts to find new drug leads for NTDs, our lab discovered the novel natural
product naranjamide [figure 4C]. Naranjamide is a linear peptide containing six amino
acids, including a terminal N,N-dimethyl valine and a C-terminal dolaphenine.

Figure 4C: naranjamide

4.2.1. Isolation Procedure
An orange cyanobacterium sample collected by hand using SCUBA in Portobelo,
Panama was extracted using a 2:1 DCM:MeOH mixture to yield a crude extract (extract
code 2002, mass 4.2 g). The extract was tested for its antiprotozoal activity [table 4B]
and was found to inhibit P. falciparum growth by 82.6 % at a concentration of 10
µg/mL. The extract was then fractionated by forced-air column chromatography and the
fraction obtained with 1:1 EtOAc:MeOH (fraction 2002H, mass 69.4 mg) showed growth
inhibition of both P. falciparum (97.5 %) and T. cruzi (75.0 %) at a concentration of 10
µg/mL. Further fractionation by C18 Sep-Pak yielded a fraction eluting with 80 %
MeOH in H2O (fraction 2002H4, mass 8.5 mg), which showed growth inhibition of P.
falciparum (79.6 %) and T. cruzi (81.5 %) at a concentration of 10 µg/mL, with an IC 50
of 6.36 µg/mL for T. cruzi. This fraction was then purified with reverse-phase HPLC
using a gradient of 50-100% AcN in H2O (fraction 2002H4D) to yield 0.8 mg of pure
compound, which was given the trivial name naranjamide [figure 4D] [see figure 4D for
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fractionation procedure]. Due to lack of material and difficulty in obtaining
reimportation permits for the natural product, the pure natural product was not
screened following its isolation.
Fraction

L. donovani

P. falciparum

T. cruzi

MCF-7

2002

4.7

82.6

16.7

28.2

2002H

13.7

97.5

75.0

13.6

2002H4

NT
79.6
81.5
NT
Table 4B: Antiprotozoal Activity of 2002 Fractionation (% Growth Inhibition)

Figure 4D: Purification of Naranjamide

4.2.2. Structure Elucidation
The structure of naranjamide was determined in our lab using extensive NMR
experiments [figures 4E-4H; see section 6.2. for more information on NMR
experiments] as well as high resolution mass spectrometry and MS/MS experiments
[figure 4I]. The stereo-configurational analysis by Marfey’s was not completed due to
lack of material.
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Figure 4E: 1H-NMR of Naranjamide

79
Figure 4F: HSQC of Naranjamide
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Figure 4G: 1H-1H COSY of Naranjamide
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Figure 3H: HMBC of Naranjamide

The HRMS of fraction
2002H4D gave an M + of
685.44576, matching a
theoretical mass of 685.44695,
and chemical composition of
C37H 61O4N6S.

figure 4I: HRMS and MS/MS of Naranjamide
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The structure of naranjamide was determined as a linear peptide containing six amino
acids [Figure 4C]. The C-terminus is composed of condensed phenylalanine and
cysteine residues, called dolaphenine; the thiazole ring is formed by condensation of the
cysteine sulfur and phenylalanine carbonyl, followed by dehydration, and oxidative
decarboxylation [figure 4J]. The same dolaphenine unit is seen in other cyanobacterial
natural products, such as dolastatin 10 [figure 4B]. Naranjamide is also capped on the
N-terminus with an N,N-dimethyl valine, which is present in a large number of bioactive
cyanobacterial peptides, like gallinamide A [figure 4B]. Of the six amino acids present in
the molecule, three are N-methylated, another common characteristic of cyanobacterial
natural products [figure 4B].

Figure 4J: Proposed Thiazole Formation Mechanism

The NMR spectra of naranjamide were very convoluted. This is likely due to the slowly
free-rotating benzyl in the dolaphenine unit, in addition to the rigidity brought on by the
N-methylations [figure 4K]. Looking into the HSQC [Figure 4F], there are four benzylic
protons, one pair similar to but with a weaker signal than the other two. This led us to
believe that the spectrum was actually made up of two pseudo-atropisomers; the
dolaphenine would be shielding the remainder of the molecule in a different manner,
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depending on the position of the aromatic ring in comparison to the rest of the
molecule, namely the N-methyl groups and residue side chains. As the initial isolation
was of a single peak on the HPLC, we think that the spectrum represents pseudoatropisomers, and not two distinct atropisomers that are separable. Atropisomers are
stereoisomers arising because of hindered rotation about a single bond, where energy
differences due to steric strain or other contributors create a barrier to rotation that is
high enough to allow for isolation of individual conformers. A way to verify this and to
deconvolute the NMR spectra would have been to increase the temperature while
collecting NMR data.

Figure 4K: Rotation of Dolaphenine on Naranjamide

The MS/MS results verified the amino acid sequence that was proposed based on NMR
[figure4I].
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4.2.3. Synthesis of Naranjamide and Analogs
A total synthesis of the molecule was attempted for two main reasons. First, NMR
spectra were very convoluted [discussed in section 4.2.2.], and synthesis with known
precursors would allow to verify the NMR assignments as well as determine the
stereochemistry, as cyanobacteria are known to include D-amino acids as well. Second,
more material would allow extensive biological testing, to determine efficacy and
potency, mechanism of action, and cytotoxic activity of this novel molecule.
A small-scale synthesis of naranjamide and several analogs, including a nonmethylated
and a fully N-methylated, were attempted in our lab, and the products were tested for
activity against L. donovani, P. falciparum, and T. cruzi.

4.2.4. Activity of Naranjamide and Analogs
Synthetic naranjamide and two synthetic analogs were tested for activity against L.
donovani, P. falciparum, and T. cruzi, as well as cytotoxicity against MCF-7 and Vero
cancer cell lines [table 4C]. Synthetic naranjamide was found to possess antimalarial
activity with an IC50 of 2.8 µM against the W2 chloroquine-resistant strain of P.
falciparum, and an IC50 of 9.2 µM against T. cruzi; it was inactive against L. donovani.
Synthetic naranjamide was also shown to have cytotoxic activity, with a 90.3 %
inhibition of growth for MCF-7 cancer cell line. The fully methylated analog of
naranjamide [figure 4L] was found to have lost activity for malaria, while maintaining
cytotoxicity. The nonmethylated analog of naranjamide [figure 4L] was found to be
almost as potent and efficacious at inhibiting P. falciparum growth; however, activity
against T. cruzi was lost. The synthetic nonmethylated analog also lost its cytotoxic
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activity, which led to our conclusion that this molecule was not generally toxic, but was
selectively killing the malaria parasite, while the natural product may be effective
against P. falciparum because of general cytotoxic activity.
This preliminary data showing efficacy, potency, and selectivity made the
nonmethylated naranjamide analog an ideal candidate for further investigation as a lead
for an antimalarial drug. Further testing to evaluate the activity, selectivity, and
mechanism of action of naranjamide and its synthetic analogs needed to be completed.
For this, and for verifying the complete structure of naranjamide, a large-scale synthesis
of naranjamide and its synthetic nonmethylated analog were attempted.

Figure 4L: Fully Methylated (top) and Non-Methylated (bottom) Naranjamide Analogs

Molecule

Leishmania

Malaria

Chagas

MCF-7

Vero

Synthetic
Naranjamide

>200 µg/mL

2.8 µM
1.9 µg/mL

71.5% GI
9.23 µM
6.32 µg/mL

90.3% GI

22.89 µM
15.68 µg/mL

Nonmethylated
Naranjamide

Out of range

14.46 µM
9.3 µg/mL

12.23% GI

0

-

Methylated
Naranjamide

>200 µg/mL

57.08 µM
39.9 µg/mL

3.27% GI

0

-

Table 4C: Activity of Naranjamide Analogs
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4.2.5. Synthesis of Naranjamide: Old Method
The synthesis of naranjamide was initially envisioned as a convergent synthesis [figure
4M], with a methylated tripeptide (KN4me) comprising the right piece of the molecule
condensing with a dipeptide (KN6) of the left piece of the molecule. Synthesis [figure
2N] involved building the BOC-protected tripeptide using BOC-protected isoleucine,
methyl-ester valine, and dolaphenine unit, followed by methylation of the tripeptide,
and BOC-deprotection, as well as building a left piece using N,N-dimethyl valine and
methyl-ester valine, followed by deprotection of the methyl-ester. The synthesis of the
nonmethylated analog [figure 2O] would be similar, without the methylation reaction.

Figure 4M: Naranjamide Original Retrosynthetic Scheme
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Figure 4N: Naranjamide Synthesis: Old Method
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Figure 4O: Nonmethylated Naranjamide Synthesis: Old Method

In synthesizing the intermediate KN3me, methylation of the tripeptide was difficult.
According to mass spectrometry, it is likely that there were partial methylations of the
peptide, with masses reflecting single and double methylations, as well as failure of
methylation, in addition to the desired trimethylated peptide KN3me [figure 4P]. To get
full methylation of the tripeptide, 10 equivalents of base and 25 equivalents of methyl
iodide were used, with several reaction batches requiring multiple methylation
attempts. Previous attempts were made increasing the equivalents of base and methyl
iodide, however, overmethylation occurred, methylating the thiazole nitrogen.
In both the original and nonmethylated analogs, deprotection of the BOC group to yield
KN4me and KN4 was difficult, and several attempts were made to get higher yields. The
harsh acidic conditions of TFA in DCM hydrolyzed the peptide seemingly at the same
rate of deprotection, leaving similar amounts of the free amine, the single amino acids,
and the unreacted KN3me and KN3, respectively, as seen on mass spectrometry [figure
4P). Shorter reaction times as well as low temperatures were used, but proved
inefficient. Using HCl in MeOH did not show improved results.
Two attempts at the final coupling reaction of KN4me and KN6 were made, but were
unsuccessful. Mass spectroscopy after an initial attempt using EDC and HOBt with
DIPEA in DCM showed the reaction did proceed at all. A second attempt using HATU in
DMF with DIPEA also failed, and with DMF being very difficult to remove, the reaction
mixture turned into an inseparable oil and was tossed. Several attempts were made to
couple KN4 and KN6 of the nonmethylated analog. While coupling secondary amines is
known to be difficult or provide lower yields, coupling of the primary amine KN4 with
KN6 also provided low yields of up to 17%. Multiple attempts included coupling reagents
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like EDC/HOBt, CIP/HOBt, and HATU, in DCM with DIPEA [table 4D]. Likely, the
lower yields of the final coupling reaction were a result of incomplete BOC deprotection.
N3me
ESI+

N4
ESI+

Figure 4P: MS of Naranjamide Intermediates: Old Method

Coupling Reagents

Yield of Final Coupling

HATU/DIPEA in DMF83

0% (N7me)

EDC/HOBt/DIPEA in DCM

0% (Nme7), 17% (N7)

CIP/HOBt/DIPEA in DCM84

6% (N7)

HATU/DIPEA in DCM

15% (N7)

Table 4D: Final Coupling Reaction Reagents and Yields
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Ultimately, a question of racemization arose, questioning whether the harsh basic
methylation conditions were causing racemization of KN3me. It was then that a
seemingly pure N4me product was injected onto the HPLC, showing multiple peaks
[figure 4Q], indicating that racemization was indeed occurring. Looking into the
literature, any of the methyl ester deprotections using sodium hydroxide,85 methylations
using sodium hydride, or BOC deprotections using TFA or HCl, could have caused a
number of racemizations at nearly every step of the tripeptide synthesis. At this point,
the synthesis method was revised.

Figure 4Q: Racemization of KN4me as seen on HPLC
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4.2.6. Synthesis of Naranjamide: New Method
To avoid racemization, an alternate synthetic pathway was developed which included Nmethylated, FMOC-protected amino acids [figure 4R]. FMOC-protected and Nmethylated-FMOC-protected amino acids are readily available in large quantities at
affordable prices due to use in automated peptide synthesis. Premethylated amino acids
allow to avoid the harsh basic conditions of the methylation reaction, and FMOC
protection requires 4-methylpiperidine, a softer and more specific base, for
deprotection. The peptide was then assembled from the dolaphenine unit to the N,Ndimethyl valine, with five peptide coupling steps.
N-methylated dolaphenine (KN1), required for synthesizing the natural product, was
synthesized by protecting the dolaphenine amine with BOC, followed by methylation
(KN2), and BOC deprotection (KN3). Without BOC protection, the primary amine
would have been overmethylated to form a quaternary nitrogen with three methyl
groups attached; each methyl group would have made the nitrogen more reactive.
The methylation of dolaphenine proved to be difficult; the reaction was extremely
sensitive to humidity and moisture, providing yields between 0-90% depending on
moisture levels in the lab, despite efforts to dry glassware and reagents, and running the
reaction under inert atmosphere. The BOC deprotection proved difficult yet again,
however, as a single amino acid, the reaction could run for a longer duration without
worrying about peptide hydrolysis.
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Figure 4R: Naranjamide Synthesis: New Method

Because dolaphenine has a single chiral center, potential racemization occurring during
the previous two reactions could potentially lead to two enantiomers, inseparable by
HPLC. However, the subsequent coupling reaction with N-methyl valine (KN4) would
create diastereomers, allowing separability.
From there, three additional peptide coupling reactions with subsequent FMOC
deprotections would be used to add N-methyl-isoleucine, valine, and finally N,Ndimethyl valine. Two attempts were made at the first coupling reaction, condensing Nmethyl dolaphenine and N-methyl valine: the first, using CIP/HOBt in DCM, which gave
the product in low yield (~15%), the second, using CIP/HOBt in DCM with DIPEA,
which did not give any product at all.
Due to time restraints (and global events at this time), the project was halted after the
first coupling reaction (KN4).
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4.2.7. Synthesis of Nonmethylated Naranjamide: New Method
The nonmethylated analog of naranjamide was also synthesized [figure 4S]. The
synthetic scheme consisted of four coupling reactions, with subsequent FMOCdeprotections, similar to those of the natural product synthesis, starting with the
coupling of dolaphenine and FMOC-valine (KuN1), and followed by couplings of FMOCisoleucine (KuN3), FMOC-valine (KuN5), and N,N-dimethyl valine (KuN7). In this
synthesis, the peptide couplings were of primary amines versus of secondary amines,
making the couplings faster and more efficient. HOBt and EDC were used in coupling
reactions, with yields of 70-80%. As the peptide grew it became more hygroscopic and
was also slower to dissolve in DCM for the coupling reactions, so a few drops of MeOH
were added to the penultimate and final steps of the reaction sequence.
Initially, the FMOC-protected intermediates were chosen to perform NMR
characterizations on, however, the FMOC, much like the dolaphenine, skewed the NMR
and made it more difficult to read. Therefore, after purifying the FMOC-protected
intermediates to >95%, they were deprotected and purified via flash column
chromatography. Due to time restraints and (global events at this time), the free amine
intermediates were not fully purified on HPLC, and the resulting MS and NMR spectra
are not reflective of a pure product, with the NMRs difficult to interpret. [See figures
4T1-7 and 4U1-4 for additional information.]
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Figure 4S: Nonmethylated Naranjamide Synthesis: New Method

4.2.8. Structure-Activity Relationship of Naranjamide Analogs
The three analogs tested for antiprotozoal activity and general cytotoxicity showed
varying results [see table 4C]. While the natural product showed efficacy against P.
falciparum and T. cruzi as well as general cytotoxicity, methylation in just one
additional amino acid led to complete inactivity. Meanwhile, the nonmethylated analog
showed selective activity against P. falciparum, without detectable cytotoxicity. These
differences in activities are likely due to the methylation pattern.
The antimalarial activity is likely due to the dolaphenine, while the methylation pattern
leads to cytotoxic activity. The natural product, while having antimalarial activity, could
be hindering a normal cellular activity by way of the amide methylations; a regular cell
cannot digest this molecule, and it incorporates into and destroys normal proteinprotein interactions. The nonmethylated product, however, while having the same
antimalarial activity in the protozoal cells, would not harm human (cancer) cells because
the human body can hydrolyze and digest the peptide, as it includes regular amide
bonds.
This can be easily verified by synthesizing additional analogs of naranjamide. The
syntheses of the two analogs can be altered by using different amino acids in the
addition sequence, allowing to create an analog library. Specifically, it would be
interesting to create analogs without the dolaphenine unit, as well as with a benzyl
(phenylalanine) or a thiazole moiety alone, to determine its requirement for activity, as
was seen with the crucial methoxypyrrolinone moiety in gallinamide A. These analogs
could then be tested on a panel of falcipains and other proteases found in the parasite.
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4.3. Conclusions
Neglected tropical diseases effect over one billion people and cost developing economies
billions of dollars each year.70 Available treatments are often ineffective, with severe side
effects or resistance development. With warming climates and frequent travel, more and
more populations will be susceptible to these diseases. Development of new and
effective therapies are therefore an important task.
Nature has provided us with a plethora of natural products, some of which have shown
encouraging results when tested against the protozoa responsible for these diseases. We
have discovered a novel cyanobacterial natural product with activity against P.
falciparum, the malaria-causing protozoa. In order to confirm its structure and to test
its activity and mechanism of action against the parasite, a total synthesis was
attempted. Synthesis of a nonmethylated analog was also attempted, with the product
displaying selectivity for P. falciparum and no detectable general cytotoxicity. This
natural product is one of many cyanobacterial natural products that have been found to
have activity against neglected tropical disease parasites, including malaria.
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4.4. Experimental Procedures
4.4.1. Synthetic Materials
All reagents and HPLC-grade solvents were purchased from Sigma Aldrich or Thermo
Fisher and used without further purification, unless stated otherwise. Dolaphenine was
purchased from Chemscene.
CIP

2-chloro-1,3-dimethylimidazolidinium hexafluorophosphate

DIPEA

N,N-diisopropylethylamine

DMF

dimethylformamide

EDC

1-ethyl-3-(3-dimethylaminopropyl)carbodiimide

HATU

hexafluorophosphate azabenzotriazole tetramethyl uranium

HOBt

hydroxybenzotriazole

TFA

trifluoroacetic acid

4.4.2. General Procedure for Peptide Coupling
4.4.2.1. For Primary Amines
FMOC-protected carboxylic acid (1.1eq) was added with HOBt (1.2 eq) and EDC (1.2 eq)
to DCM, stirring for 30 minutes at 0°C. After 30 minutes, the amine∙HCl (1 eq) was
added with DIPEA (3 eq). The reaction was stirred overnight, warming to room
temperature. The reaction mixture was then diluted with DCM, washed with citric acid,
NaHCO3, and H2O. It was then dried in vacuo, and the product purified via Biotage
Isolera™ column chromatography using a normal phase KP-Sil 10 g column.
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4.4.2.2. For Secondary Amines
FMOC-protected carboxylic acid (2 eq) was added with HOBt (1 eq) and DIPEA (6 eq) to
DCM, stirring for 5 minutes at RT. After 5 minutes, the secondary amine (1 eq) was
added with CIP (2 eq). The reaction was stirred for 3 hours at RT. The reaction mixture
was then diluted with DCM, and washed with citric acid, NaHCO 3, and H2O. It was then
dried in vacuo, and the product purified via Biotage Isolera™ column chromatography
using a normal phase KP-Sil 10 g column.

4.4.3. General Procedure for FMOC Deprotection
FMOC-protected amine was dissolved in 10:1 v/v DCM:4-methylpiperidine solution (~1
mL per 100 mg), and the reaction stirred for one hour. The reaction mixture was then
dried in vacuo, and the product purified via Biotage Isolera™ column chromatography
using a normal phase KP-Sil 10 g column.

4.4.4. General Procedure for HPLC Purification
The product was loaded onto a reverse phase Synergi-fusion 4µ, 150x10 mm column
from Phenomenex on a Dionex UltaMate 3000, starting with 70% MeOH in H2O for 1.5
minutes, then a gradient of 70-100% MeOH in H2O over 15 minutes, followed by 100%
MeOH for four minutes.
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4.4.5. Reaction Procedures: Nonmethylated Naranjamide (KuN7)
4.4.5.1. KuN1: (9H-fluoren-9-yl)methyl ((S)-3-methyl-1-oxo-1-(((S)-2-phenyl-1(thiazol-2-yl)ethyl)amino)butan-2-yl)carbamate
Reaction was carried out per section 4.4.2.1.; the product eluted at 2% MeOH in DCM. It
was then purified per section 4.4.4. with retention time of 15.5 minutes.
KuN1: white solid. Yield: 80%, 112 mg, 0.21 mmol.
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[M+H+] 526.4
calc 526.2159
[M+Na+] 548.4
calc 548.1978

Purity:
98.13%

Figure 4T1: KuN1 1H-NMR, MS, HPLC
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4.4.5.2. KuN2: (S)-2-amino-3-methyl-N-((S)-2-phenyl-1-(thiazol-2-yl)ethyl)butanamide
Reaction was carried out per section 4.4.3.; the product eluted at 12% MeOH in DCM.
KuN2: white solid. Yield: 90%, 57 mg, 0.19 mmol.

KuN2

valine

dolaphenine

#

H
[ppm]

#, m, J [Hz]

C
[ppm]

1

N

-

-

2

7.723

0.94, d, 3.1

142.2

3

7.171

5.95, m

119.1

4

S

-

-

5

C4

-

171.5

6

5.581

0.95, dd, 7.6

52.2

7

3.247,
3.322

1.06, dd, 7.1
1.06, dd, 7.1

41.2

8

C4

-

136.5

9

7.171

5.95, m

128.5

10

7.171

5.95, m

129.3

11

7.171

5.95, m

126.9

12

7.171

5.95, m

129.3

13

7.171

5.95, m

128.5

14

8.533

0.86, d, 8.1

-

15

-

-

170.8

16

3.496

0.92, d, 5.0

59.4

17

2.113

0.98, m, 6.7

30.6

18

0.75

2.86, d, 6.7

18.8

19

0.85

3.00, d, 6.7

16.8

20

-

-

-

Table 4E: 1 H-NMR for KuN2
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[M+H+] 304.3
calc 304.1478
[M+Na+] 326.3
calc 326.1298

KuN2 collection
(stopped due to
global situation)

Figure 4T2: KuN2 1H-NMR, MS, HPLC
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4.4.5.3. KuN3: (9H-fluoren-9-yl)methyl ((2S,3S)-3-methyl-1-(((S)-3-methyl-1-oxo-1(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)amino)butan-2-yl)amino)-1-oxopentan-2yl)carbamate
Reaction was carried out per section 4.4.2.1.; the product eluted at 2% MeOH in DCM. It
was then purified per section 4.4.4. with retention time of 17.0 minutes.
KuN3: white solid. Yield: 66%, 78 mg, 0.12 mmol.
This product was very jelly-like and difficult to try down. It was left under air
overnight and dried into a fine powder which blew out onto the bench, losing a
significant amount of it. Some of it was recovered and repurified.

[M+H+] 639.5
calc 639.3000

Purity:
95.17%

Figure 4T3: KuN3 MS and HPLC
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4.4.5.4. KuN4: (2S,3S)-2-amino-3-methyl-N-((S)-3-methyl-1-oxo-1-(((S)-2-phenyl-1(thiazol-2-yl)ethyl)amino)butan-2-yl)pentanamide
Reaction was carried out per section 4.4.3.; the product eluted at 3% MeOH in DCM.
KuN4: white solid. Yield: 90%, 46 mg, 0.11 mmol.

[M+H+] 417.4
calc 417.2319
[M+2Na-H+] 461.5
calc 461.1958

Figure 4T4: KuN4 1H-NMR and MS
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4.4.5.5. KuN5: (9H-fluoren-9-yl)methyl ((S)-3-methyl-1-(((2S,3S)-3-methyl-1-(((S)-3methyl-1-oxo-1-(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)amino)butan-2-yl)amino)1-oxopentan-2-yl)amino)-1-oxobutan-2-yl)carbamate
Reaction was carried out per section 4.4.2.1.; the product eluted at 5% MeOH in DCM. It
was then purified per section 4.4.4. with retention time of 17.4 minutes.
KuN5: white solid. Yield: 79%, 68 mg, 0.09 mmol.

[M+H+] 738.0
calc 738.3684
[M+Na+] 760.0
calc 760.3503

Purity:
95.46%

Figure 4T5: KuN5 MS and HPLC
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4.4.5.6. KuN6: (2S,3S)-2-((S)-2-amino-3-methylbutanamido)-3-methyl-N-((S)-3methyl-1-oxo-1-(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)amino)butan-2yl)pentanamide
Reaction was carried out per section 4.4.3.; the product eluted at 7% MeOH in DCM.
KuN6: white solid. Yield: 90%, 42 mg, 0.08 mmol.

[M+H+] 516.2
calc 516.3003
[M+Na+] 538.2
calc 538.2828

Figure 4T6: KuN6 1H-NMR and MS
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4.4.5.7. KuN7: nonmethylated naranjamide: (2S,3S)-2-((S)-2-((S)-2-(dimethylamino)3-methylbutanamido)-3-methylbutanamido)-3-methyl-N-((S)-3-methyl-1-oxo1-(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)amino)butan-2-yl)pentanamide
Reaction was carried out per section 4.4.2.1, with 1:1 MeOH:DCM. It was then purified
via Biotage Isolera™ column chromatography using a 5g ZIP Sphere column; the
product eluted at 25% MeOH in DCM.
KuN7: white solid. Yield: 22%, 11 mg, 0.017 mmol.
The column used for purification malfunctioned during the loading; an unknown
amount of the product was lost.

[M+H+] 642.8
calc 643.4000
[M+Na+] 664.8
calc 665.3819
Figure 4T7: KuN7 1H-NMR and MS
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4.4.6. Reaction Procedures: Naranjamide (KN10)
4.4.6.1. KN1: tert-butyl (S)-(2-phenyl-1-(thiazol-2-yl)ethyl)carbamate
Salted amine was deprotonated via liquid-liquid extraction with NaOH, and then
reacted with BOC2O (2 M in DCM) in DCM for 2 hours. It was then dried in vacuo, and
purified via flash column chromatography; the product eluted at 20% EtOAc in
Hexanes.
KN1: white solid. Yield: 100%, 266 mg, 0.875 mmol.
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[M+H+]
305.3
calc
305.1318

Purity:
95.49%

Figure 4U1: KN1 1H-NMR, MS, HPLC
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4.4.6.2. KN2: tert-butyl (S)-methyl(2-phenyl-1-(thiazol-2-yl)ethyl)carbamate
BOC-protected dolaphenine (KN1, 1 eq) was stirred in THF under N 2 for one hour. After
one hour, MeI (8 eq) was added, and stirred under N 2 at 0°C for an additional 30
minutes. Then, NaH (3 eq) was carefully added to the solution, and the solution was
stirred under N2 at 0°C overnight. The reaction mixture was then diluted with EtOAc
and neutralized to pH7 with HCl. The organic layer was then dried in vacuo, and the
product extracted with DCM from water. It was then dried in vacuo, and purified via
flash column chromatography; the product eluted at 15% EtOAc in Hexanes.
KN2: light orange oil. Yield: 90%, 250 mg, 0.78 mmol.
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[M+Na+]
341.2
calc 341.1294

Purity:
98.66%

Figure 4U2: KN2 1H-NMR, MS, HPLC
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KN1

BOC-dolaphenine

#

H [ppm]

KN2

#, m, J [Hz]

H [ppm]

#, m, J [Hz]

1

N

-

N

-

2

7.77

1H, d,

7.80

1H, m

3

7.51

1H, m

7.61

1H, m

4

S

-

S

-

5

C4

-

C4

-

6

5.16

1H, dd/q,

5.73
5.86

½H, dd,
½H, dd,

7

3.01
3.41

1H, dd,
1H, dd,

3.28
3.59

1H, dd,
1H, m

8

C4

-

C4

-

7.26

5H, m

7.29

5H, m

14

NH

-

2.73

3H, s

15

1.32

9H, “d”

1.34

9H, “dd”

9
10
11
12
13

Table 4F: KN1 & KN2 1 H-NMR
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4.4.6.3. KN3: (S)-N-methyl-2-phenyl-1-(thiazol-2-yl)ethan-1-amine
Product (3) is dissolved in DCM, and TFA is added 1:1 (1 mL per 10 mg product).
Reaction is run for 30 minutes, or as needed determined by TLC. The reaction mixture
was then neutralized with NaOH, the organic layer extracted with DCM. It was then
dried in vacuo, and purified via flash column chromatography, the product eluting at
25% EtOAc in Hexanes.
KN3: colorless oil. Yield: 88%, 149 mg, 0.68 mmol.

[M+H+] 219.6
calc 219.0950

Figure 4U3: KN3 MS
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4.4.6.4. KN4: (9H-fluoren-9-yl)methyl methyl((S)-3-methyl-1-(methyl((S)-2-phenyl-1(thiazol-2-yl)ethyl)amino)-1-oxobutan-2-yl)carbamate
Reaction was carried out as per section 2.2.1.2. (General Procedure for Peptide Coupling
for Secondary Amines). It was then purified via flash column chromatography, the
product eluting at 40% EtOAc in Hexanes.
KN4: colorless oil. Yield: 16%, 62 mg, 0.11 mmol.
Not pure, possibly two diastereomers. Purification was not completed due to global
events at this time.

[M+H+] 553.4
calc 554.2472
[M+Na+] 575.4
calc 576.2291

Figure 4U4: KN4 MS
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4.4.7. Instruments
4.4.7.1. NMR Spectroscopy
Experiments for intermediates were recorded on a Bruker 500 spectrometer at 499.60
MHz for 1H and 125.62 MHz for 13C.
Experiments for Naranjamide (1H, 13C, 1H-COSY, HSQC, HMBC, HSQC-TOCSY,
NOESY, CLIP-HSQC, DOSY) were recorded on a Bruker 500 spectrometer at 500 MHz
for 1H and 125.73 MHz for 13C at Carnegie Melon University.
Samples were dissolved in CD3OD and CDCl3 and tested in standard 5mm diameter
NMR tube at room temperature. Chemical shifts are reported in δ values, [ppm] units,
relative to the standard TMS (δ=0), and coupling constants reported in [Hz]. [See
section 6.1. for more details.]

4.4.7.2. Mass Spectrometry
Mass spectra were recorded on an Advion Expression Benchtop Mass Spectrometer
using Electro Spray Ionization (ESI).
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4.4.8. Assays
4.4.8.1. Leishmania (Leishmania donovani) Bioassay
Axenically grown (cell free) amastigotes of Leishmania donovani WR2801, a kind gift
from Max Grogl (Experimental Therapeutics Division, Walter Reed Army Institute of
Research, Silver Spring, MD, USA), were used to assess parasite growth and survival.
Samples were tested in duplicates at 10 g/mL. The results were expressed as a
percentage of growth inhibition (GI) compared to controls. Samples that showed over
70% GI were considered active and were then assayed at four different concentrations
(0.08, 0.4, 2, and 10 g/mL) to determine IC50 values. Amphotericin B was used as a
positive control with an IC50 value response of 80-120 ng/mL.

4.4.8.2. Chagas (Trypanosoma cruzi) Bioassay
Trypanosoma cruzi bioassays were performed using a colorimetric method, and the
growth inhibition of the parasite was assessed by the expression of the reporter gene for
-galactosidase (-Gal) in the recombinant Tulahuen clone C4 of T. cruzi from The
American Type Cell Collection (ATCC). Assays were performed in duplicates on the
amastigote stage, which is the intracellular form of the parasite infecting African green
monkey kidney (Vero) cells, exposed during 120 h to different concentrations (10, 2, and
0.4 g/mL) of the test compounds at 37C under an atmosphere of 5% CO 2 in air. The
resulting color from the cleavage of chlorophenol red--D-galactoside (CPRG) by -Gal
expressed by the parasite was measured at 570 nm. The concentration that inhibited
50% expression of -Gal (IC50) was calculated by log regression of the obtained optical
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density values and compared with the untreated controls. Nifurtimox was used as a
positive control (IC50 2-5 g/mL).

4.4.8.3. Malaria (Plasmodium falciparum) Bioassay
Antiplasmodial activity was evaluated using a fluorometric method based on the
detection of parasite DNA with the fluorochrome PicoGreen. The chloroquine-resistant
strain Indochina W2 (a generous gift of The Walter Reed Army Institute of Research,
Silver Spring, MD) of Plasmodium falciparum was used for the crude extract and
subsequent fractions. For the synthetic product, the chloroquine-sensitive HB3 strain
obtained from the Malaria Research and Reference Reagent Resource Center (MR4,
Manassas, VA, USA) was used. All initial screenings were performed at 10g/mL. The
IC50 value was calculated by normal regression of the resulting inhibition percentages at
0.08, 0.4, 2, and 10 g/mL. Parasites were maintained in vitro by a modification of the
method of Trager and Jensen, synchronizing the parasites with alanine. Chloroquine
was used as a positive control (IC50 80-100 nM for W2 and 15-26 nM for HB3).

4.4.8.4. Cytotoxicity Assay
The reduction of tetrazoliom MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) was used to assess the viability of cells. 5×103 cells in 100
µL of media per well are cultured in 96-well plates and let incubate at 37°C for 24 hours
before adding 50 µL of different concentrations of the target molecules. For screening,
only 10 µg/mL final concentration was used. A negative control, without any sample but
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with equal volume of the vehicle was used. Cells are incubated 48 hours longer before
performing the MTT assay. Absorbance values were determined in a Synergy HT plate
reader (BioTek Instruments, Winooski, VT) employing a 570 nm test wavelength and a
650 nm reference filter. The IC50 was calculated using the Data Analysis Wizard
complement of Excel 2000 (Microsoft, Seattle, USA).

4.4.8.5. MCF-7 Cell Line Assay
The MCF-7 mammalian breast cancer cell line was obtained from ATCC. On the day
prior to the bioassay, 5×103 cells were seeded in a final volume of 100 µL/well in 96-well
plates and incubated with RPMI-1640 supplemented with gentamicin (0.05 mg/mL), Lglutamine (GIBCO; 2 mM), NaHCO 3 (4.6 mM), HEPES buffer (25 mM), and FBS (10%)
at 37°C. For each bioassay, 100 µL of the extract was diluted in culture media, added to
the cells, and incubated for 48 h at 37°C. Cells were fixed with tricholoroacetic acid
(50%), and treated with sulphorhodamine B (0.4%), which was allowed to react for 1530 min at 22°C. The cells were then rinsed with acetic acid (1%), dried, and treated with
Tris-HCl (10 mM, pH 7) for 15 min. Color intensity was read at 570 nm. The positive
control used was adriamycin (normal IC50 value is approximately 20-50 nM).
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5. Conclusions
Humans have used plants, plant extracts, and pure natural products as medicines to
treat pain and disease since at least 5000 BC when we have evidence of the first written
recording of their use. Natural products are produced by organisms to aid their own
overall fitness, allow communication between species, and deter and attract prey. These
compounds have evolved to interact with various biological targets, as their producers
evolved alongside their target organisms, leading to highly selective and potent
compounds. After centuries of terrestrial pharmacognosy, scientists started looking in
the ocean and other aquatic environments for natural products. One major benefit of
natural products from these sources is that for natural products to be effective in water,
these compounds would need to be especially potent.
Marine cyanobacteria evolved billions of years ago and today higher order species with
large genomes have the ability to produce a plethora of compounds, including peptides
and macrolides. These natural products have been shown to have effects on human CNS
receptors, including the dopamine receptors, as well as antiproliferative effects, against
cancers, bacteria, and protozoa responsible for diseases like malaria and Chagas’
disease.

Dopamine has a central role in the nervous system and is involved in a variety of
functions and disorders. Of the five dopamine receptors, the D5 receptors is perhaps the
least researched, as its similarity and scarcity compared to the D1 receptor makes
specified targeting of it more difficult. While cyanobacteria have been shown to
incorporate the amino acid tyrosine, the precursor of dopamine, into their natural
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products, many natural product scientists do not screen for dopaminergic activity, or
any biogenic amine receptor activity, as part of their standard bioassays. In this
research, we have shown that cyanobacteria can produce various compounds which bind
to dopaminergic receptors, and this additional screening can be of great contribution to
the field of natural product drug discovery. While a pure natural product responsible for
this affinity has not yet been determined, our research is ongoing. Once isolated, this
selective natural product will allow us to gain insight on the role of the D5 receptor and
the molecular determinants that confer selectivity. Future studies could develop a probe
to determine the localization of these receptors, and an analog library will allow
identification of the pharmacological effects of agonistic, antagonistic, and inverse
agonist behavior at the receptor.

During the search for the compound in this extract with D5 affinity, the serendipitous
rediscovery of caylobolide A allowed us to learn about additional structure elucidation
capabilities. Caylobolide A was discovered originally in 2002, however, its full
stereochemistry has never been resolved due to the flexibility of the molecule and the
isolated positions of the hydroxyl groups in the macrolide ring. Micro electron
diffraction, a newer technique utilizing the cryo-electron microscope, would allow for
the determination of the relative stereochemistry of the molecule; combining this
information with the four known stereocenters would allow determination of the
absolute configuration of the molecule. Caylobolide A purified from the extract provided
crystals that were too small to obtain sufficient data, likely due to the flexibility of the
macrolide; future attempts at crystallization could involve chemical modifications such

123

as acetylation or benzoylation, adding rigidity to the molecule. This technique could
help solve the configuration of this and many other similar molecules.

Another option for determining the configuration of the molecule would be a total
synthesis, which is what was attempted with naranjamide. Naranjamide was discovered
in a Panamanian extract, and showed potential as an antimalarial agent, with its
synthetic nonmethylated analog showing selective toxicity against the malarial protozoa
P. falciparum. The NMR spectra of the natural product were convoluted, likely due to a
dolaphenine unit, creating two pseudo-atropisomers. A synthesis using amino acids
with known configuration would allow determination of the stereoconfiguration of the
molecule, as cyanobacteria are known to occasionally incorporate D-amino acids as well
as L-amino acids. The initial synthetic route showed a racemized mixture of products
and was ultimately changed. While these racemized products were unwanted, they could
potentially help study the target and determine the configuration needed for achieving
optimal selectivity and activity. An alternate synthetic route was then designed for the
natural product and the nonmethylated analog. The synthetic products can then be
tested for activity and mechanism of action, helping to understand the selectivity of the
nonmethylated analog and its cellular target.

This thesis presents my work combining natural products chemistry with medicinal
chemistry to better understand the interactions of compounds with their biological
targets. Isolation and structure elucidation are the tools of natural products chemistry to
identify new leads and treatments. Synthesis and Analog design are the tools of
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medicinal chemistry to understand and optimize those interactions. The projects
presented here are a combination of the two fields and display how natural products and
medicinal chemistry can be used together to better understand and treat disease.

125

6. General Experimental Procedures

6.1. Synthetic Materials
All reagents and HPLC-grade solvents were purchased from Sigma Aldrich or Thermo
Fisher and used without further purification, unless stated otherwise.

6.2. Nuclear Magnetic Resonance
Nuclear magnetic resonance (NMR) is one of the most powerful tools for structure
elucidation. Along with data received from UV, IR, MS, and other analytical techniques,
NMR aids in determining the final structure of a compound in question.
NMR experiments generally divide into two groups: one-dimensional (1D) and twodimensional (2D). A 1D spectrum is an expression of the signal versus time or frequency
(obtained after performing a Fourier transform over time). This type of experiment
examines one type of nucleus, for example 1H or 13C [see figure 3E for example]. A 2D
spectrum includes two different types of nuclei, and two dimensions of frequency
(again, obtained after Fourier transform). This type of experiment allows to study
correlations between chemical shifts of same or different nuclei, for example 1H and 1H,
or 1H and 13C. Correlations of bonds between two to five atoms apart can be examined,
depending on the type of experiment.
In this study, the following 2D NMR experiments were performed:

126

6.2.1. HSQC: 13C-1H Correlation
HSQC (Hetereonuclear Single Quantum Correlation) correlates 13C nuclei with directly
attached (coupled) protons; these are one-bond (1JCH) couplings [see figure 3G for
example]. The frequency domains are of different nuclei, so there is no apparent
diagonal or symmetry. The essential difference between HSQC and HMQC is that, while
the HSQC experiment is carbon detected, the HMQC is proton detected. Since there are
great discrepancies between proton and carbon in their relative abundances and
sensitivities, HMQC is greatly preferred today.

6.2.2. COSY: 1H-1H Correlation
COSY (COrrelation SpectroscopY) is the simplest 2D experiment. The peaks shown on
the experiment correlate coupled protons [see figure 3H for example].

6.2.3. HMBC: 1 H-13C Long Range Correlation
HMBC (Heteronuclear Multiple Bond Coherence) is proton detected and capitalizes on
these two- and three-bond couplings providing an extremely powerful (and sometimes
cluttered) spectrum [see figure 3I for example]. In essence, carbon-carbon correlations
are indirectly obtained. Both 2JCH and 3JCH couplings are present, and interpretation can
be tedious. HSQC correlations must be kept in mind.
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6.2.4. TOCSY
TOCSY (Totally Correlated SpectroscopY) show all coupled nuclei within the same spin
system. This experiment has the same appearance as a COSY, with proton showing on
both axes, but will show all protons for the spin system. For longer mixing times, all
spins within a spin system will appear coupled; shorter mixing times will show shorter
bonds.

6.2.5. HSQC-TOCSY
HSQC-TOCSY is a type of “hybrid” 2D correlation experiment that combines features of
two simpler 2D experiments. HSQC-TOCSY correlates one-bond H-C couplings (HSQC)
but shows these correlations throughout an entire spin system (TOCSY) [see figure 3J
for example]. This experiment simplifies complex carbohydrate and peptide systems
and allows ready assignments of systems of protons and carbons.
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6.3. Mass Spectrometry
Mass spectrometry (MS) determines the molecular weight of a compound. The
commonly used electron-impact (EI) mode works by bombarding molecules in a vapor
phase with a high-energy electron beam, causing molecules to ionize, and then records
the result as a spectrum of positive or negative ions, which have been separated on the
basis of mass/charge (m/z) [see figure 3D for example].

6.4. Column Chromatography
Liquid column chromatography separates molecules based on different characteristics
they have, such as size, polarity, or chirality. The chromatographic strategies used in our
lab use polarity to separate molecules, and date back at least as far back as 1996, with
the discovery of barbamide by the Gerwick lab. 86 The general procedure for
chromatographic purification uses normal phase flash column chromatography, eluting
with a non-polar to polar solution, using hexanes, ethyl acetate, and methanol, followed
by reverse phase column chromatography using methanol or acetonitrile in water, and
lastly using a more precise reverse phased HPLC with methanol or acetonitrile in water.

6.4.1. Flash Column Chromatography: Biotage Isolera™ Prime
The Biotage Isolera™ Prime allows automated separation of molecules, based on their
polarity. It also allows detection of the molecules in the sample using UV technology;
210 nm and 254 nm wavelengths were used to detect C=X double bonds and conjugated
molecules. Tubes are collected based on solvent polarity or UV detection.
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6.4.2. High Performance Liquid Chromatography: Dionex UltiMate 3000
The Dionex UltiMate 3000 allows automated, high-precision separation of molecules,
based on their polarity. It also allows detection and quantification of the molecules in
the sample using UV technology; 210 nm, 254 nm, 310 nm, and 410 nm were used to
detect C=X double bonds, conjugated molecules, and pigments, respectively.
Reverse phase HPLC using the Dionex UltiMate 3000 were performed, using a Synergifusion 4µ, 150x10mm column from Phenomenex [see figure 2K for example].

6.5. Thin Layer Chromatography
Prior to column chromatography, thin layer chromatography (TLC) was performed for
samples to determine methodology. TLC results were determined using UV light,
followed by staining with ninhydrin solution for detection of amines and amides (1.5 g
ninhydrin in 100 mL BuOH and 3 mL AcOH), or with vanillin solution for all molecules
present (1.5 g vanillin in 25 mL EtOH and 250 µL sulfuric acid), and applying heat to the
TLC plate.
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